[{"text": "LIVE The latest news and updates on Trump's tariffs Manas AI Launches to Transform Discovery of Novel Cancer Medicines Manas AI Launches to Transform Discovery of Novel Cancer Medicines \u00b7 ACCESS Newswire Manas AI Mon, Jan 27, 2025, 4:30 PM 5 min read Manas AI, a full-stack, AI-driven company focused on discovering and advancing next generation medicines, launched today. By leveraging its proprietary AI-driven platform, its partnership with Microsoft, and a world-class team of scientists across diverse disciplines, Manas AI is uniquely positioned to disrupt the traditional model of therapeutic discovery. The company aims to significantly accelerate the process of screening, identifying, and advancing transformative medicines for cancer, autoimmune disease, and rare conditions - including some previously considered unreachable. Co-founded by Dr. Siddhartha Mukherjee, a pioneering oncologist, researcher, and author, and Reid Hoffman, renowned entrepreneur and investor, Manas AI integrates generative computational chemistry, advanced molecular docking, and cutting-edge biology to create a full-stack therapeutic development pipeline - from target identification to clinical trials. Manas will use Microsoft's cloud computing platform, Microsoft Azure, as well as Microsoft's deep domain knowledge in AI to develop novel medicines. \"Our mission is simple yet profound: to transform how we discover and develop life-saving medicines. Through the power of AI and our world-class team, we believe we can drastically reduce the time and cost it takes to bring game-changing new treatments to patients. I am particularly excited about the novel models for generative chemistry that Manas is developing. If these generative models work, we aspire to replace conventional experimental methods to create medicines,\" said Dr. Siddhartha Mukherjee, co-founder of Manas AI. Disrupting Medical Discovery with AI and Compute Power Manas AI's proprietary approach builds on several distinctive foundations: Proprietary AI Filters and Libraries: Manas AI generates bespoke chemical libraries and utilizes advanced AI filters to identify high-potential therapeutic candidates with paradigm-shifting speed and accuracy. Massive Scale Compute: Through the Microsoft collaboration, Manas AI will build on top of the Azure cloud computing infrastructure, enabling molecular docking at speeds 100x faster than traditional systems. Project Cosmos: The company's ambitious AI-driven initiative aims to map the fundamental \"rules\" of drug binding, further accelerating the discovery of novel chemical entities. \"Amidst all the hype in AI-powered drug discovery today, Manas AI is poised to make truly practical, game-changing advances,\" said Peter Lee from Microsoft. \"It's especially exciting to integrate world-class AI capabilities with groundbreaking chemistry, biology, and wet-lab expertise as we aim to re-shape the future of medicine. Microsoft is proud to partner with Manas to help realize this critically important mission.\" Story Continues A Global Vision for Impact With an initial focus on oncology, Manas AI is developing treatments for aggressive cancers such as triple-negative breast cancer, prostate cancer, and lymphoma. Eventually, the company also intends to target other important global diseases A World-Class Team Leading a New Era of Medical Discovery Manas AI has brought together a world-class, interdisciplinary team of leaders in the discovery of novel medicines - spanning AI, computational chemistry, biology, and clinical research. The team includes five members of the National Academy of Sciences, four members of the National Academy of Medicine, and two recipients of the Breakthrough Prize in Life Sciences. The Manas team features an unprecedented assembly of globally significant, influential contributors to scientific and medical innovation, including: Dr. Lew Cantley (Harvard University), discoverer of PI3K and PTEN, scientific founder of Agios Pharma Dr. Gary Gilliland (Fred Hutch), former Global Oncology Franchise Head, Merck & Co., groundbreaking researcher on the genetic underpinnings of cancer Dr. William Jorgensen (Yale University), world leading innovator in computational chemistry whose contributions have transformed molecular simulation and drug design Dr. Peter Kim (Stanford University), pioneering biochemist and former President of Merck Research Laboratories, where he oversaw approval of over 20 new medicines Dr. Craig Mello (UMass Chan Medical School) co-discoverer of RNA interference and 2006 Nobel Laureate in Medicine, scientific co-founder of CRISPR tx, Atalanta tx and several others RNA focused biotechnology companies. Dr. Matthew Shair (Harvard University), world leading organic chemist, small molecule therapeutics expert and scientific founder of Nuvalent Dr. David Spiegel (Yale University), chemical biologist renowned for his contributions in antibody-recruiting molecules and synthetic antibody mimics for therapeutic applications \"Our interdisciplinary team is uniquely equipped to tackle the most complex challenges in drug discovery,\" said Dr. Mukherjee. \"By combining expertise in AI and biology with best-in-class preclinical models, we can accelerate the process of discovering life-saving medicines that were once out of reach.\" Backed by Leading Investors Manas AI has raised $24.6 million in funding to accelerate its groundbreaking AI-driven drug discovery programs. The company's financing was led by General Catalyst with participation from Greylock and other strategic investors in life sciences and technology. The capital will be used to scale its proprietary AI platform, advance its pipeline of drug candidates, and expand its global clinical programs. \"As a former CEO in the biopharma industry, I'm very familiar with the challenges of the highly complex and resource-intensive therapeutic discovery model\", said Ken Frazier, chairman, health assurance initiatives, General Catalyst, and former chairman and CEO of Merck. \"Manas AI has the potential to compress the timeline to discovery of effective drug candidates while increasing the likelihood of success in clinical trials. This is a unique opportunity to dramatically change the drug discovery landscape and make a positive impact on billions of people around the world.\" \"AI will have a lasting and positive impact on humanity, and for years I have been focused on helping realize the potential of this technology. It's my honor to partner with Sid to build a company focused on using AI to transform drug discovery,\" said Reid Hoffman, co-founder and investor in Manas. \"Manas AI is breaking down barriers that have slowed medical innovation for decades, which will lead to exponential positive impact in our ability to treat human disease.\" About Manas AI Manas AI is a full-stack, AI-driven drug discovery company. By harnessing the power of proprietary AI models and leveraging extensive computational infrastructure, the company aims to dramatically reduce drug discovery timelines. Co-founded by Dr. Siddhartha Mukherjee and Reid Hoffman, and a world-class interdisciplinary team that spans AI, computational chemistry, biology, and clinical research, Manas AI is on a mission to bring life-saving treatments to patients faster than ever before. Visit manasai.co for more information. Contact Information Tamar Harel tamar@tellny.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AGIO", "date": "2025-01-27T16:30:00", "sentiment": {"score": 0.11299038492143154, "confidence": 0.13273203372955322, "probabilities": {"positive": 0.13273203372955322, "negative": 0.01974164880812168, "neutral": 0.8475263118743896}}, "embedding": [-0.13375446200370789, -0.06257473677396774, -0.034196797758340836, -0.015133735723793507, 0.044519685208797455, -0.08447316288948059, 0.05198699235916138, 0.016565799713134766, 0.18167127668857574, 0.1256197690963745, -0.22825504839420319, -0.018593303859233856, 0.05995425954461098, 0.06547515094280243, -0.11730331182479858, 0.24433770775794983, -0.036220893263816833, -0.01336829736828804, -0.16638663411140442, 0.075701504945755, 0.009620971977710724, 0.07812779396772385, -0.03215208649635315, -0.015363291837275028, -0.04262622445821762, 0.1533707231283188, -0.04361887276172638, -0.23404861986637115, -0.1825895458459854, -0.06660427153110504, 0.07609601318836212, 0.17099431157112122, -0.025414226576685905, -0.006195060908794403, -0.09351421892642975, 0.08568072319030762, -0.10594198107719421, 0.1201920211315155, -0.05209124833345413, -0.17678123712539673, 0.07399550825357437, -0.037815239280462265, -0.10216279327869415, 0.08838706463575363, 0.10757024586200714, -0.17545689642429352, -0.18869248032569885, -0.05241117626428604, 0.12402839958667755, 0.3088153600692749, -0.33114027976989746, -0.20040956139564514, -0.05228640139102936, 0.13361185789108276, -0.030855916440486908, 0.06897851824760437, 0.0008706394582986832, -0.0200684554874897, -0.022643113508820534, -0.12749983370304108, 0.17530502378940582, -0.2335205078125, 0.12177405506372452, 0.003117118962109089, 0.17796681821346283, 0.05835751071572304, 0.045928068459033966, 0.020405108109116554, 0.033039458096027374, -0.11062587797641754, 0.06699179857969284, 0.13359732925891876, -0.022174738347530365, 0.19401982426643372, 0.060618720948696136, 0.15238842368125916, 0.1222924217581749, 0.09880314767360687, 0.19534344971179962, -0.148380845785141, -0.0031231907196342945, 0.07597637176513672, 0.16073203086853027, 0.17039966583251953, -0.058877892792224884, 0.11001864075660706, -0.0028112968429923058, 0.1526567041873932, 0.14962507784366608, -0.10233030468225479, -0.0019496660679578781, -0.023521561175584793, 0.05424133688211441, -0.021241389214992523, 0.020196370780467987, -0.08568025380373001, -0.032522425055503845, -0.03481508046388626, -0.05887341871857643, 0.09317351877689362, -0.16877245903015137, 0.03960864245891571, -0.10827556252479553, -0.18179073929786682, 0.05653231963515282, -0.05870617926120758, 0.04275021702051163, -0.01831551268696785, 0.08551004528999329, -0.026763036847114563, 0.041995298117399216, 0.09825693815946579, 0.022333884611725807, -0.11923596262931824, 0.030618775635957718, 0.22690585255622864, 0.015860067680478096, 0.0405157133936882, 0.00498132174834609, 0.0668845921754837, -0.01685945875942707, -0.03656487166881561, -0.08472798764705658, -0.167451873421669, 0.01649651490151882, 0.05482977628707886, -0.17729094624519348, 5.535518243405326e-33, 0.052466981112957, 0.004314944613724947, 0.21211686730384827, 0.1076805591583252, 0.27229923009872437, -0.17128849029541016, 0.11528544127941132, -0.07796068489551544, -0.29487526416778564, -0.10981185734272003, -0.21550294756889343, 0.20886994898319244, -0.11158221960067749, 0.20424556732177734, 0.03419017419219017, -0.2076270878314972, 0.05694108456373215, -0.025724897161126137, 0.020356887951493263, -0.2615130543708801, -0.009402688592672348, -0.061161287128925323, -0.10238014161586761, -0.004852703306823969, -0.11428439617156982, 0.1986158788204193, 0.060814883559942245, 0.031541548669338226, 0.2318095564842224, 0.0410120002925396, -0.23197001218795776, 0.0678684413433075, -0.010682310909032822, -0.08201229572296143, -0.0063680862076580524, -0.07414158433675766, -0.13280880451202393, -0.13843265175819397, 0.08852207660675049, 0.1538868397474289, 0.012932417914271355, 0.06828242540359497, 0.04123155400156975, -0.0553128644824028, -0.13325941562652588, -0.02673701010644436, -0.03288674354553223, 0.0014592092484235764, 0.04224993288516998, -0.007808704860508442, -0.09039561450481415, 0.027874784544110298, 0.10020121932029724, 0.009743706323206425, -0.08163489401340485, -0.08188296854496002, -0.18887066841125488, -0.08678038418292999, 0.0782548040151596, 0.12769263982772827, -0.010659254156053066, -0.03414604812860489, -0.052648674696683884, 0.2917330265045166, -0.1292804777622223, 0.05395127087831497, 0.05548035353422165, -0.06418542563915253, 0.05450809374451637, 0.21483802795410156, -0.03145955130457878, 0.054805949330329895, 0.09386252611875534, -0.039639413356781006, 0.020357413217425346, -0.09308812022209167, 0.11130402982234955, -0.14435091614723206, -0.1530291587114334, 0.0696416050195694, -0.1710154414176941, 0.06725523620843887, -0.14066174626350403, 0.12293025851249695, -0.2149379551410675, -0.11424294114112854, -0.04995515197515488, -0.015271664597094059, -0.23225201666355133, -0.09680858999490738, -0.06831647455692291, 0.03879928216338158, 0.09670649468898773, -0.006481599994003773, -0.10083483159542084, -5.59978325424875e-33, -0.08564595878124237, -0.21211546659469604, -0.0026741514448076487, -0.007524831220507622, 0.08199556171894073, -0.026642730459570885, 0.00871389452368021, -0.14502407610416412, 0.13768863677978516, -0.07684150338172913, 0.0816575214266777, 0.07595391571521759, -0.054769329726696014, 0.04369087144732475, -0.07267853617668152, 0.10004594922065735, -0.011080150492489338, -0.11795058101415634, -0.01697561889886856, 0.06014473736286163, -0.06499415636062622, 0.3217126429080963, -0.23222872614860535, 0.032987192273139954, 0.017936747521162033, 0.08633823692798615, 0.03419218212366104, 0.035377658903598785, 0.08605954051017761, -0.0022204029373824596, -0.08281935751438141, 0.00996355339884758, -0.27235785126686096, 0.03632640466094017, -0.05056062713265419, 0.09826631098985672, 0.03367685154080391, -0.238206684589386, -0.0026298407465219498, -0.052831027656793594, 0.06749527156352997, -0.07324449717998505, -0.18904167413711548, -0.016284672543406487, 0.1743166744709015, 0.022454984486103058, -0.06860942393541336, 0.2100915163755417, 0.08284973353147507, 0.03560056537389755, 0.013402877375483513, 0.06205720454454422, -0.09114286303520203, -0.0619770884513855, -0.03875216841697693, -0.10471614450216293, 0.04778683930635452, -0.05125165730714798, -0.03655064478516579, 0.02512916550040245, -0.11706581711769104, -0.11402735114097595, 0.12098628282546997, -0.04850108548998833, -0.11242877691984177, 0.21212922036647797, 0.1368301510810852, 0.07590693235397339, -0.06060364469885826, -0.13577839732170105, -0.03148793429136276, 0.034079283475875854, -0.0314035564661026, 0.08536313474178314, -0.014475597068667412, -0.035461246967315674, -0.006249850615859032, -0.16017842292785645, -0.1457572728395462, -0.0796140655875206, 0.060454681515693665, -0.0679270327091217, 0.13554906845092773, -0.08147792518138885, 0.08612649142742157, 0.08959918469190598, 0.11578269302845001, -0.05169334262609482, -0.16214798390865326, 0.1114586889743805, -0.14301158487796783, -0.13914507627487183, -0.16680312156677246, 0.1885717809200287, -0.08120720088481903, -9.972575298888842e-08, 0.13126909732818604, 0.04929914325475693, 0.053683534264564514, -0.10487201809883118, 0.07853787392377853, 0.10173024237155914, -0.029400425031781197, 0.1795901656150818, -0.03875692933797836, 0.038715660572052, 0.04103900492191315, 0.011971186846494675, -0.051592595875263214, 0.053723402321338654, 0.1006569191813469, 0.10446661710739136, 0.06254753470420837, 0.04358222335577011, -0.13513222336769104, -0.12457945942878723, -0.02693401835858822, 0.14425793290138245, 0.075257308781147, -0.11470617353916168, 0.1713072955608368, -0.13589368760585785, 0.01781061291694641, -0.077512726187706, -0.0004922784864902496, 0.03126883506774902, -0.003956470172852278, 0.020526330918073654, 0.1195368766784668, 0.14721086621284485, 0.09365065395832062, -0.017982225865125656, 0.06096938997507095, -0.034394606947898865, -0.035942722111940384, 0.13338182866573334, -0.02090410515666008, 0.1904786080121994, -0.1383940726518631, -0.07919012755155563, -0.07641805708408356, -0.13039004802703857, -0.02185896597802639, -0.06355363130569458, 0.09400578588247299, 0.12952852249145508, 0.06470753252506256, -0.001737450249493122, 0.14103397727012634, 0.010448789224028587, 0.12102407217025757, 0.16685713827610016, -0.06612677872180939, -0.14579586684703827, 0.0404142327606678, 0.019305787980556488, 0.19173383712768555, -0.07417527586221695, 0.19156980514526367, -0.03573475405573845], "changes": {"1wk": 1.896294487847222}}, {"text": "LIVE The latest news and updates on Trump's tariffs METLEN achieves \u20ac295.5m FID for bauxite, alumina and gallium production in Greece The investment plan targets an annual production capacity of two million tonnes (mt) of bauxite \u00b7 Mining Technology GlobalData Fri, Jan 17, 2025, 3:05 PM 2 min read METLEN Energy & Metals has taken the final investment decision (FID) on a \u20ac295.5m ($304.1m) investment in bauxite, alumina and gallium production. The investment was approved on 16 January 2025 in a joint session with the company's Capital Allocation Committee. It will be implemented at the historic Aluminium of Greece plant in Agios Nikolaos, Viotia. This project aims to enhance production capacity and introduce gallium into industrial production for the first time. The capital expenditure includes developing new bauxite deposits, constructing gallium production facilities, expanding alumina production, and upgrading energy and port infrastructure. The investment plan targets an annual production capacity of 2 million tonnes (mt) of bauxite, 1.26mt of alumina and 50 metric tonnes of gallium. The production of these vital materials, valued at approximately \u20ac1bn, will be shipped to markets in Europe and North America. The investment also incorporates environmentally friendly technologies to reduce the carbon footprint and aims to achieve sustainable energy costs through synergies with METLEN's energy operations. METLEN chairman and CEO Evangelos Mytilineos said: \u201cThe decision by METLEN to proceed with the implementation of a new, landmark industrial investment in the production of bauxite, alumina and gallium, strengthens Europe\u2019s self-sufficiency in critical raw materials and bolsters Greece\u2019s strategic position on the global landscape. \u201cMoreover, it shields the European industry from external dependencies. We are proving our commitment to innovation, sustainable development and circular economy, while reaffirming METLEN\u2019s role as a leader in the transition toward greener and more resilient industrial production.\u201d The completion of works and production start-up is scheduled for 2026 for bauxite, with alumina and gallium production beginning gradually from 2027 and full-scale operation by 2028. Gallium, a by-product of certain bauxite qualities, is predominantly produced in China. However, China's export restrictions on gallium, imposed in July 2023, have underscored the need for Europe to diversify its supply sources. METLEN's investment aims to eliminate Europe's reliance on gallium imports, enhancing strategic autonomy. The company has submitted the project under Greece\u2019s Strategic Investments Law. The investment also meets the Temporary Crisis and Transition Framework criteria. The project has received the European Commission\u2019s STEP SEAL, recognising its contribution to EU self-sufficiency in critical raw materials. Story Continues \"METLEN achieves \u20ac295.5m FID for bauxite, alumina and gallium production in Greece\" was originally created and published by Mining Technology , a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AGIO", "date": "2025-01-17T15:05:00", "sentiment": {"score": 0.8364092819392681, "confidence": 0.8438537120819092, "probabilities": {"positive": 0.8438537120819092, "negative": 0.0074444301426410675, "neutral": 0.14870183169841766}}, "embedding": [-0.13592633605003357, -0.07502654939889908, -0.013870330527424812, 0.05168626829981804, 0.07426229864358902, -0.20422667264938354, -0.006908126175403595, 0.015128931030631065, -0.15953516960144043, -0.050565313547849655, -0.11967369168996811, -0.11105377972126007, 0.019654739648103714, -0.0419599674642086, -0.08160565048456192, 0.07905282080173492, -0.036134690046310425, -0.030960900709033012, -0.23724794387817383, 0.12646323442459106, 0.23097844421863556, -0.07507934421300888, 0.09898773580789566, 0.08251822739839554, 0.0433826670050621, 0.11106111854314804, 0.015263665467500687, -0.11948683857917786, -0.13261249661445618, -0.06749075651168823, -0.04230394959449768, 0.24238592386245728, 0.031424202024936676, -0.036344874650239944, -0.005078205838799477, 0.07234132289886475, -0.12851077318191528, 0.07077444344758987, -0.08173646032810211, -0.12844571471214294, -0.09565641731023788, -0.014230890199542046, 0.05968189239501953, -0.06787747144699097, -0.14208389818668365, -0.07918849587440491, 0.030579453334212303, -0.012499995529651642, 0.04910793900489807, -0.035548433661460876, -0.05570906400680542, -0.07206188142299652, -0.08643709123134613, -0.08650846034288406, -0.09261006116867065, 0.02750513330101967, -0.018385684117674828, -0.04623813182115555, 0.0033951629884541035, 0.04128009080886841, 0.0599040724337101, -0.1137567013502121, 0.04454922676086426, -0.11412182450294495, 0.1593751609325409, -0.001172749325633049, -0.1681181788444519, -0.1608695387840271, -0.2274860441684723, 0.04913955181837082, 0.16524331271648407, -0.16182807087898254, -0.1005808413028717, -0.09051352739334106, -0.01219549123197794, 0.22149300575256348, 0.2517276406288147, 0.02071661874651909, 0.09257921576499939, -0.09386344254016876, -0.03374801576137543, 0.0815606415271759, 0.025130392983555794, -0.1617831438779831, 0.004524759948253632, 0.06758520007133484, 0.10832038521766663, 0.09347160160541534, 0.13666284084320068, -0.021838923916220665, 0.07798321545124054, 0.044302862137556076, -0.1629563271999359, 0.04154413938522339, 0.10112923383712769, 0.1468202769756317, 0.08597433567047119, 0.17574039101600647, -0.0236857570707798, 0.031378373503685, 0.14447224140167236, 0.04474300891160965, -0.012870056554675102, -0.10470698773860931, -0.2054429054260254, -0.04646166041493416, 0.02294611930847168, 0.03567236661911011, -0.029693424701690674, 0.042957011610269547, 0.11534076929092407, -0.07947666943073273, 0.04470188915729523, -0.20671255886554718, -0.1159682422876358, 0.16970688104629517, -0.056459564715623856, -0.16241440176963806, 0.16930212080478668, -0.11326676607131958, 0.08941841125488281, 0.04274711012840271, -0.03628785163164139, 0.04069141298532486, -0.026703055948019028, 0.003138689324259758, -0.10915149748325348, 1.1791953213174546e-32, -0.12883883714675903, -0.08761954307556152, -0.06768515706062317, 0.017861422151327133, -0.18651919066905975, 0.008504806086421013, -0.04688329994678497, 0.03056761808693409, -0.1014786958694458, -0.2281266152858734, -0.10846215486526489, 0.14618197083473206, -0.001258918084204197, 0.0011495044454932213, 0.16150063276290894, -0.217148095369339, 0.23501893877983093, -0.025486700236797333, 0.15399350225925446, 0.001199924387037754, 0.0003959785681217909, -0.12563171982765198, -0.07750938832759857, 0.197098970413208, 0.07231605052947998, 0.07661251723766327, 0.16135601699352264, -0.17237162590026855, -0.1786920428276062, 0.04336606711149216, 0.07041697204113007, 0.14731428027153015, -0.10971124470233917, -0.022323252633213997, -0.17519286274909973, 0.06784157454967499, -0.17798157036304474, 0.01326093077659607, -0.20676997303962708, -0.08443190157413483, 0.0601234994828701, 0.11337962746620178, -0.0557747446000576, 0.15707240998744965, -0.013783836737275124, -0.005972135812044144, -0.027894511818885803, 0.19437876343727112, 0.08236736059188843, -0.05672580748796463, -0.04936247691512108, 0.1452675759792328, 0.03248719498515129, -0.13430733978748322, -0.008236164227128029, 0.02299482375383377, 0.02908514067530632, -0.10711977630853653, 0.12600694596767426, 0.049281470477581024, -0.09012490510940552, 0.1333737075328827, -0.0435393825173378, 0.3047262728214264, -0.14670351147651672, 0.19138696789741516, 0.09301896393299103, 0.1704588532447815, -0.07962377369403839, 0.021885577589273453, -0.0846230536699295, -0.12592266499996185, 0.21362587809562683, 0.08472040295600891, -0.0224363524466753, 0.12430033087730408, 0.17469891905784607, -0.0571865513920784, 0.009773867204785347, 0.038355421274900436, -0.16158178448677063, 0.09315118938684464, -0.05129944905638695, -0.1989668905735016, -0.10589522123336792, -0.07474389672279358, -0.03927703946828842, 0.1377628743648529, 0.09184032678604126, -0.045536335557699203, 0.037826523184776306, -0.048418208956718445, 0.0443430095911026, 0.07731107622385025, -0.11165457963943481, -1.1809556241078109e-32, 0.08935275673866272, -0.040012892335653305, -0.0005530416965484619, -0.1323200762271881, -0.06721185147762299, -0.03797309845685959, -0.039456404745578766, -0.14560672640800476, 0.009641360491514206, -0.06279925256967545, -0.06205959618091583, -0.04006674885749817, 0.121503084897995, -0.07215014100074768, -0.10751539468765259, 0.029656708240509033, 0.10111105442047119, -0.02368435263633728, -0.026603002101182938, -0.010575436055660248, 0.016126129776239395, 0.32530900835990906, -0.10692872107028961, -0.013697627931833267, -0.1304883062839508, -0.030167289078235626, -0.022944781929254532, -0.02085731364786625, 0.0576464869081974, -0.06868758797645569, -0.048549264669418335, 0.028323225677013397, -0.1473308801651001, 0.06396950036287308, -0.08569355309009552, -0.024813048541545868, 0.11158884316682816, -0.0828133374452591, 0.020236052572727203, 0.14009417593479156, 0.020082978531718254, 0.0497589111328125, -0.03963632881641388, 0.12514926493167877, 0.05128724128007889, -0.09121863543987274, 0.004891176708042622, -0.09410595893859863, 0.051174700260162354, -0.029773347079753876, 0.15911206603050232, 0.02938438206911087, 0.008938535116612911, -0.19500844180583954, -0.010663820430636406, 0.10968656837940216, -0.032732076942920685, 0.061403654515743256, -0.11595061421394348, -0.01796114444732666, 0.106096550822258, 0.08762510120868683, 0.2491205334663391, 0.0021230243146419525, 0.012171871960163116, 0.135075181722641, -0.06230911985039711, 0.017536764964461327, -0.012503225356340408, -0.05896690860390663, -0.09762915968894958, 0.10270370543003082, -0.07954210042953491, 0.0958908200263977, 0.06080106645822525, 0.05586637556552887, 0.14631617069244385, -0.004597123712301254, -0.032926157116889954, -0.05366123840212822, 0.0388907827436924, 0.10755367577075958, 0.12165062129497528, -0.04651457071304321, 0.12625259160995483, -0.03166601434350014, -0.011463823728263378, -0.037122901529073715, 0.009936792775988579, 0.06399888545274734, -0.2364014834165573, -0.11321894824504852, 0.010640211403369904, 0.16486267745494843, -0.009845994412899017, -1.0012645645929297e-07, -0.08812253177165985, 0.06948222219944, 0.0045057013630867004, 0.057619284838438034, 0.06901125609874725, -0.08874429017305374, 0.05857875198125839, 0.08821550756692886, 0.15042772889137268, 0.07813090831041336, -0.1209460198879242, -0.0004828928504139185, -0.054154377430677414, 0.0157917607575655, -0.06810227036476135, 0.12906786799430847, -0.07425853610038757, 0.0034416939597576857, -0.03631299361586571, -0.04745370149612427, 0.2410118281841278, -0.04555942863225937, 0.040568381547927856, 0.06714040786027908, -0.04308687895536423, -0.1135130301117897, 0.053394488990306854, 0.07381004840135574, -0.065529465675354, 0.046047642827034, -0.05475166067481041, -0.015256538987159729, 0.0894797295331955, -0.03424990177154541, 0.08758191764354706, -0.09689413011074066, 0.051165711134672165, 0.019016271457076073, 0.09481403231620789, 0.12434107065200806, -0.07072173804044724, -0.15065573155879974, 0.061089351773262024, -0.06001011282205582, -0.06476745754480362, -0.13462023437023163, -0.3510870337486267, -0.12916545569896698, 0.1293066293001175, 0.0873529314994812, 0.004470023326575756, 0.020002415403723717, 0.11462584137916565, 0.057913780212402344, 0.19817641377449036, 0.08118803054094315, -0.0006169491680338979, -0.010830944404006004, -0.0774102732539177, 0.015795383602380753, 0.2031012624502182, -0.13065749406814575, 0.08518660068511963, 0.008106634020805359], "changes": {"1wk": 9.130176022049469}}, {"text": "LIVE The latest news and updates on Trump's tariffs Innofactor wins contract to provide the case and document management system for a leading Swedish technical university Innofactor Plc Tue, Jan 21, 2025, 3:00 PM 2 min read In This Article: IFA1V.HE 0.00% Innofactor Plc Innofactor Plc press release January 21, 2025, at 14:00 Finnish time A leading Swedish technical university based in northern Sweden has chosen Innofactor Dynasty in a public procurement to deliver a system for information management, containing document and case management, records management and meeting management, including hosting as a SaaS cloud service. After a thorough evaluation, the university has chosen Innofactor Dynasty to deliver and manage a system that is sustainable, adapted for Swedish higher education institutions and of high quality. Dynasty\u2019s functions are well designed and managed, containing functions and nomenclature to support working methods at higher education institutions, and where all the components involved are secure, well implemented, tested and documented. The contract period is two years, in addition to which there are ten one-year options, which are decided separately. The total value of the procurement (excluding VAT) stated by the Customer in the procurement decision is approximately SEK 9.5 million. Offers by the deadline were submitted by Innofactor AB, Sokigo AB, Tietoevry AB, Agio System och Kompetens AB and Formpipe Software AB. The parties will work together to ensure that the packaging of Innofactor Dynasty can be offered to other higher education institutions in Sweden. \u201cThis collaboration benefits both parties. The university receives a standard solution that supports its diverse needs. Innofactor, on the other hand, expands its customer base, which promotes the continuous development of Innofactor Dynasty to meet the needs of higher education institutions\u201d, sums Malin Sundin , Business Manager at Innofactor. The implementation has started in December 2024 and the planned start of production is scheduled after the summer of 2025. Read more about Innofactor Dynasty: https://www.innofactor.com/what-we-do/our-solutions/dynasty/intro/ Additional information: Vesa Niinist\u00f6, Managing Director, Innofactor Tel. +358 40 543 7869 vesa.niinisto@innofactor.com Innofactor Innofactor is the leading driver of the modern digital organization in the Nordic Countries for its about 1,000 customers in commercial and public sector. Innofactor has the widest solution offering and leading know-how in the Microsoft ecosystem in the Nordics. Innofactor has about 600 enthusiastic and motivated top specialists in Finland, Sweden, Denmark and Norway. www.innofactor.com #AIDriven #PeopleFirst #BeTheRealYou View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AGIO", "date": "2025-01-21T15:00:00", "sentiment": {"score": 0.4044514326378703, "confidence": 0.41167280077934265, "probabilities": {"positive": 0.41167280077934265, "negative": 0.00722136814147234, "neutral": 0.5811058282852173}}, "embedding": [-0.14663636684417725, 0.09271807968616486, 0.016258621588349342, -0.20475712418556213, -0.10826869308948517, -0.04314674437046051, -0.048876531422138214, 0.16294623911380768, 0.11497937142848969, 0.06764457374811172, 0.13426467776298523, -0.07416163384914398, 0.07356779277324677, -0.030175358057022095, 0.07490053027868271, -0.00898415595293045, -0.10024885088205338, -0.08683356642723083, -0.12997549772262573, 0.035027340054512024, 0.03816781938076019, -0.06614896655082703, -0.09304097294807434, -0.09575717151165009, -0.02903253398835659, 0.016985254362225533, -0.0247141532599926, -0.10681694746017456, -0.12679705023765564, -0.21831321716308594, 0.02648233063519001, 0.13172292709350586, 0.02627069130539894, -0.039171695709228516, 0.06151413917541504, 0.0925963819026947, -0.06333449482917786, -0.03525106608867645, -0.04644756764173508, -0.04625213146209717, -0.07885852456092834, -0.04007048159837723, -0.021549690514802933, -0.044100962579250336, 0.05337248742580414, 0.05179445445537567, -0.0848548635840416, -0.03852095827460289, 0.007010469678789377, 0.14302419126033783, -0.2306171953678131, -0.043310243636369705, 0.08993798494338989, 0.07192632555961609, -0.02927025593817234, -0.04189644753932953, 0.0019130227155983448, 0.0800836980342865, -0.09227544814348221, 0.011594575829803944, 0.000250338576734066, 0.02029268443584442, -0.11510202288627625, -0.04156532883644104, -0.01120094396173954, -0.0620223730802536, -0.016093354672193527, -0.026892216876149178, -0.13487474620342255, 0.012875312007963657, 0.11246515810489655, -0.15843625366687775, -0.0957416296005249, 0.036767471581697464, 0.004438890144228935, 0.027318548411130905, 0.022079644724726677, 0.053972966969013214, 0.09864482283592224, -0.14275985956192017, 0.15303707122802734, 0.15680700540542603, -0.09163510799407959, -0.09422194957733154, -0.10745909065008163, -0.009749578312039375, 0.06550316512584686, -0.015194895677268505, 0.14913338422775269, -0.029511842876672745, 0.02268237993121147, -0.12487970292568207, 0.004230055026710033, -0.0029513328336179256, 0.09815052151679993, 0.010622434318065643, 0.07626613974571228, 0.12973466515541077, 0.0904848724603653, 0.07961000502109528, 0.023051148280501366, -0.02454487979412079, -0.01843409426510334, -0.09220299869775772, -0.20707252621650696, -0.01865714229643345, -0.03762789070606232, 0.035624824464321136, 0.04431552439928055, -0.03385693579912186, -0.11908623576164246, -0.08875437080860138, -0.06727514415979385, -0.15532974898815155, -0.0011612805537879467, 0.12350696325302124, 0.05251005291938782, 0.02230626530945301, 0.10676136612892151, -0.14302286505699158, 0.13668927550315857, 0.03279229998588562, 0.024440543726086617, -0.035329241305589676, -0.04563485085964203, -0.01950795017182827, 0.010774650610983372, 1.1682534525580161e-32, -0.0893983393907547, 0.019937261939048767, -0.22351932525634766, 0.00907998625189066, -0.03753145784139633, -0.10373403131961823, -0.005141879431903362, 0.1598946899175644, -0.18347400426864624, -0.001881963573396206, -0.14218226075172424, 0.03420349210500717, -0.15718717873096466, -0.03337901085615158, 0.1228535920381546, -0.13365042209625244, -0.01708964630961418, 0.06490858644247055, 0.0448685847222805, 0.04042002931237221, 0.08654281497001648, -0.01870686560869217, 0.07625380903482437, 0.05888272821903229, 0.11230263859033585, -0.04349087178707123, 0.08150021731853485, -0.019500594586133957, -0.02811199240386486, -0.024505775421857834, 0.14533932507038116, -0.03074819967150688, -0.050627607852220535, -0.06838708370923996, -0.03140031918883324, 0.04708472639322281, -0.11304911226034164, -0.0848429948091507, 0.07173557579517365, -0.03630727902054787, -0.09282255172729492, 0.056252747774124146, -0.0670374259352684, 0.03845759481191635, 0.0704832449555397, 0.032185301184654236, 0.033578287810087204, -0.003919648937880993, 0.12917491793632507, -0.03992447257041931, -0.09323541820049286, 0.001624704571440816, -0.017833642661571503, -0.04328226298093796, 0.05263347923755646, 0.03805220127105713, 0.009851652197539806, 0.0003499547019600868, 0.05401458591222763, 0.15904277563095093, -0.07742343097925186, 0.024392319843173027, 0.03794053569436073, 0.14202354848384857, -0.051677994430065155, -0.08290553092956543, -0.00015140254981815815, -0.03674231469631195, 0.17807865142822266, -0.14301884174346924, -0.02957228012382984, -0.1279124617576599, 0.10011367499828339, 0.010819818824529648, 0.030261624604463577, -0.0036553004756569862, -0.07951775193214417, 0.1276402771472931, -0.04703377187252045, -0.031230811029672623, -0.07472367584705353, 0.09636124968528748, -0.02618935890495777, 0.013603340834379196, 0.02467687614262104, 0.05719371140003204, 0.0948379710316658, -0.03567484766244888, 0.03437631577253342, 0.04092957824468613, 0.07115457952022552, -0.013317834585905075, -0.057494714856147766, 0.17332395911216736, 0.18172156810760498, -1.1742503839255298e-32, 0.1396048665046692, -0.08513346314430237, -0.03379686176776886, -0.022600805386900902, 0.05041370913386345, 0.11087419092655182, 0.02950383722782135, -0.013344280421733856, -0.07685766369104385, 0.012358926236629486, -0.010599540546536446, 0.00205438956618309, 0.05565934255719185, 0.03572068735957146, -0.0184335894882679, -0.04126385599374771, 0.12163552641868591, -0.11157938092947006, -0.08536724746227264, 0.09625432640314102, 0.02006254717707634, 0.16144904494285583, -0.11867527663707733, -0.0058381822891533375, -0.025040216743946075, 0.04707571119070053, -0.04900461062788963, 0.10509219765663147, 0.03864588215947151, 0.06853554397821426, -0.03207232803106308, -0.14111143350601196, -0.20376300811767578, 0.06701123714447021, 0.057181768119335175, -0.15331333875656128, 0.11558105051517487, 0.002721245400607586, -0.029854662716388702, -0.0028724470175802708, 0.12656298279762268, -0.03213540464639664, -0.0363193079829216, 0.007583986036479473, 0.025883516296744347, -0.14448100328445435, -0.07518087327480316, -0.11386746913194656, 0.11388884484767914, -0.11632390320301056, -0.0175127312541008, 0.04721273109316826, 0.07710045576095581, -0.07956744730472565, 0.045952945947647095, 0.05934663861989975, 0.025020133703947067, -0.006876346655189991, -0.13845868408679962, 0.061213262379169464, 0.1190706342458725, 0.01306314580142498, 0.1439950168132782, 0.009998384863138199, 0.11083375662565231, 0.08212428539991379, 0.050676945596933365, -0.0490368977189064, -0.0821528285741806, -0.08874987065792084, 0.020524078980088234, -0.09705406427383423, 0.04202509671449661, -0.1317591667175293, 0.12715692818164825, -0.021977953612804413, 0.013249358162283897, -0.021131372079253197, -0.009869826957583427, -0.11608783155679703, 0.03647752106189728, -0.014422306790947914, 0.020794924348592758, -0.004944116808474064, -0.001337159425020218, -0.000505129573866725, 0.1275472790002823, -0.10228721052408218, 0.01520741917192936, -0.07507763803005219, 0.0013568054419010878, -0.00732995942234993, -0.008462632074952126, 0.04671325907111168, 0.0060124825686216354, -1.0063104127766564e-07, -0.04572167247533798, -0.06517583876848221, -0.02430788055062294, -0.076069675385952, 0.037293314933776855, -0.17996111512184143, 0.0003578225150704384, 0.08752216398715973, 0.02932000160217285, 0.11510838568210602, 0.08320556581020355, 0.07510314881801605, -0.0913897231221199, -0.0398792028427124, 0.07589825987815857, 0.06476322561502457, -0.0614318773150444, 0.11186295002698898, -0.08624914288520813, 0.029631052166223526, 0.0660104900598526, -0.00769470538944006, 0.015094595029950142, -0.048055339604616165, -0.014487242326140404, 0.023283855989575386, 0.05466790497303009, 0.07797004282474518, 0.11657635867595673, 0.07966901361942291, 0.0008802707307040691, -0.011654923669993877, 0.0705757662653923, -0.08585011959075928, 0.06778927147388458, -0.10079777985811234, 0.02695307321846485, 0.05383998900651932, 0.08251024782657623, 0.03558805584907532, 0.07053609192371368, -0.07269914448261261, -0.02439938113093376, 0.03691492974758148, 0.040860366076231, -0.055137112736701965, -0.20453879237174988, -0.10995141416788101, 0.05367964506149292, 0.039302289485931396, -0.0894041508436203, 0.015874791890382767, 0.08456607162952423, 0.06925583630800247, 0.06793640553951263, -0.022331856191158295, 0.025693312287330627, -0.017699867486953735, 0.019910819828510284, 0.12608471512794495, 0.12037254869937897, -0.13077151775360107, 0.13778609037399292, 0.08578769862651825], "changes": {"1wk": 1.5648524373367376}}, {"text": "LIVE The latest news and updates on Trump's tariffs Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential Noor Ul Ain Rehman Tue, Jan 14, 2025, 12:29 AM 5 min read In This Article: AGIO -2.25% We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential . In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ) stands against other top small cap stocks to buy with the highest upside potential. What Would 2025 Look Like for Small Cap Stocks? On December 30, MJP Wealth Advisors chief investment officer Brian Vendig appeared on Yahoo! Finance\u2019s Catalysts to discuss the potential outlook of small cap stocks in 2025. He said that as long as the economy stays stable and policy decisions are not taken to the extreme, small cap stocks could see the perfect environment to outperform in 2025. However, a little cooperation from the Fed is essential to maintaining this perfect environment. He also believed that the market is likely to come back to earnings. Vendig explained that the market is expected to be choppy in the first few months of 2025. This trend is likely to materialize throughout the first half of 2025, with the choppiness attributed to policy uncertainties. But Vendig believed that if earnings remain intact, he will likely stay constructive on stocks. He even thinks that bonds might be a good opportunity as well. He said: \u201cI\u2019m definitely not one to recommend to add to megacap tech at this point, but I think taking a look at some of those value-oriented sectors that help to play into innovation and growth for the economy still makes sense.\u201d He also highlighted that potential opportunities may emerge in the industrial sectors, such as infrastructure, electric grid enhancements, and power generation, along with some in pharmaceuticals and biotech. Will the Fed and Incoming Trump Administration Bolster Small Cap Stocks? Several other analysts have similar predictions as Vendig\u2019s. On December 24, Global Advisors\u2019 managing partner, Tom Lee, appeared on CNBC and highlighted the potential of small and mid-cap stocks in 2025, saying that this year will likely be a positive one for these companies. He reasoned that the incoming Trump administration and interest rate cuts are likely to make companies more expansionary, boosting their confidence regarding mergers. He even said that small caps may outperform by more than 100% in the coming years. Our Methodology We used the Finviz stock screener to compile a list of 30 small cap stocks. We then selected the top 10 stocks with the highest analyst upside potential as of January 9, 2025. We have also included the market capitalization of the stocks as of the same date. The list is sorted in ascending order of analysts\u2019 average upside potential. These stocks are also popular among elite hedge funds as of fiscal Q3 2024. Story Continues Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter\u2019s strategy selects 14 small cap and large cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). Top 10 Small Cap Stocks to Buy with the Highest Upside Potential Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ) Analyst Upside: 62.57% Market Cap: $1.97 billion Number of Hedge Fund Holders: 24 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company that focuses on cellular metabolism and classical hematology. Based in Cambridge, Massachusetts, the company engages in investigational therapies in preclinical development. The company recently received $1.1 billion in milestone payments after the FDA\u2019s approval of vorasidenib, which originated at Agios Pharmaceuticals (NASDAQ:AGIO) and is an anti-cancer drug. These payments include a $905 million payment from Royalty Pharma in association with the vorasidenib royalty purchase agreement that Agios Pharmaceuticals (NASDAQ:AGIO) announced in May 2024. It also includes a $200 million payment from Servier in connection with Agios Pharmaceutical\u2019s (NASDAQ:AGIO) divestiture of its oncology business in 2021. Apart from these milestone payments, the company has cash, cash equivalents, and marketable securities of around $1.7 billion as of Q3 2024. The company expects to use this total balance, along with the anticipated interest income and product revenue, to prepare for the potential launch of its PYRUKYND therapy for thalassemia and sickle cell disease. PYRUKYND holds the potential to become the first therapy approved for all thalassemia subtypes. The company also has plans to use its financial independence to advance its existing programs and opportunistically expand its pipeline. It takes the third spot on our list. Meridian Growth Fund stated the following regarding Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in its Q2 2024 investor letter : \u201cAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a leader in cellular metabolism and pyruvate kinase activation pioneering therapies for rare diseases. The stock appreciated in the quarter after it announced positive Phase 3 testing results of mitapivat, a therapy for adults with non-transfusion dependent thalassemia, an anemia blood disorder. With these results, we expect an FDA filing for the drug in the back half of this year for approval. The company also sold its 15% royalty on a cancer drug, which provided a boost to its cash position that could be used to further develop and market mitapivat. We trimmed our position in the company based on our valuation discipline as the share price appreciated.\u201d Overall, AGIO ranks 3rd on our list of top 10 small cap stocks to buy with the highest upside potential. While we acknowledge the potential of small cap stocks, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AGIO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AGIO", "date": "2025-01-14T00:29:14", "sentiment": {"score": 0.6883762581273913, "confidence": 0.7033284306526184, "probabilities": {"positive": 0.7033284306526184, "negative": 0.01495217252522707, "neutral": 0.2817193567752838}}, "embedding": [-0.14256194233894348, -0.09591366350650787, 0.13976892828941345, 0.023001331835985184, 0.21251541376113892, -0.04761543124914169, 0.01625976897776127, 0.18763117492198944, -0.026983581483364105, -0.011319052428007126, -0.1177491694688797, 0.1356877088546753, -0.012462770566344261, -0.008773017674684525, -0.08405456691980362, -0.0006315973587334156, 0.003221494145691395, -0.04217187687754631, -0.10895635187625885, 0.058638930320739746, -0.056171875447034836, -0.061436727643013, 0.010513203218579292, -0.10030443966388702, 0.038261398673057556, 0.05693052336573601, -0.0006180582568049431, -0.021360095590353012, -0.22820131480693817, -0.04183734953403473, -0.001255858107469976, 0.09372054040431976, 0.05960593372583389, -0.02513764426112175, -0.09210065752267838, 0.16097891330718994, -0.06574806571006775, 0.13686653971672058, 0.21546334028244019, -0.1133236289024353, 0.05879358574748039, -0.12178884446620941, -0.009030988439917564, -0.05708405002951622, -0.029984645545482635, -0.16298320889472961, 0.06781265139579773, -0.16044838726520538, -0.0391865149140358, -0.08029448240995407, -0.12509888410568237, -0.11606869846582413, 0.005005283746868372, -0.04542198032140732, -0.10442088544368744, 0.08281613141298294, -0.10240128636360168, -0.15528494119644165, 0.047861360013484955, 0.1502639800310135, 0.015373061411082745, -0.19399508833885193, 0.03656111657619476, -0.00390030350536108, 0.22841060161590576, -0.003400653600692749, 0.09952788800001144, 0.05270690098404884, -0.16754880547523499, 0.02862011454999447, 0.11523617804050446, -0.04624449461698532, -0.06225203350186348, -0.07001811265945435, 0.003164430847391486, 0.10381289571523666, 0.0522933304309845, 0.14079101383686066, 0.22632533311843872, -0.018441878259181976, 0.0006440207362174988, 0.06131254509091377, -0.037674155086278915, -0.13712981343269348, -0.27397871017456055, 0.018688730895519257, -0.01791428029537201, -0.021460767835378647, 0.015896981582045555, -0.0077573684975504875, 0.036024317145347595, 0.036876384168863297, -0.08069129288196564, 0.035074979066848755, 0.022963158786296844, 0.14013329148292542, -0.10218864679336548, -0.07467228174209595, -0.051998041570186615, 0.017126698046922684, 0.22152096033096313, 0.15920525789260864, 0.004289834760129452, -0.07492108643054962, -0.0667104423046112, -0.14883559942245483, 0.055513203144073486, -0.13798394799232483, -0.055648285895586014, -0.0026658126153051853, -0.04546365141868591, 0.12428627908229828, -0.10220488905906677, -0.03828396275639534, -0.1378912478685379, 0.0527634471654892, -0.005699619650840759, -0.08286145329475403, 0.03185389190912247, -0.09731614589691162, -0.010077537037432194, 0.10742105543613434, -0.09781405329704285, -0.06281214207410812, 0.09693293273448944, 0.10569807142019272, -0.18954609334468842, 1.0942809889603111e-32, 0.023156100884079933, 0.06962037086486816, -0.02722368761897087, 0.007880070246756077, -0.06155627220869064, 0.1537129282951355, 0.04315854609012604, -0.098247230052948, -0.15664687752723694, 0.020982040092349052, -0.186967134475708, 0.15012910962104797, -0.06329844892024994, -0.008353824727237225, 0.13386031985282898, -0.22353887557983398, 0.03249150887131691, 0.015382660552859306, 0.05820949003100395, -0.11806625872850418, -0.011075099930167198, -0.0026915352791547775, -0.0625840574502945, 0.00023426266852766275, 0.09063013643026352, 0.029055120423436165, 0.06863011419773102, -0.07213138043880463, 0.0052215103060007095, 0.07684430480003357, -0.1808072030544281, 0.24803802371025085, -0.07030893117189407, 0.013499478809535503, -0.08820649981498718, -0.04385128989815712, -0.2224004566669464, -0.05227760598063469, 0.02136397548019886, -0.0583941712975502, 0.06396343559026718, 0.3140116333961487, -0.10914897173643112, -0.03403406962752342, 0.05785477161407471, 0.013442615047097206, 0.08521861582994461, 0.16254831850528717, -0.026806188747286797, -0.04932628199458122, -0.012434101663529873, -0.03508756309747696, -0.02855844795703888, -0.13861721754074097, 0.06943120062351227, 0.033231042325496674, -0.07360652089118958, -0.10221702605485916, -0.008369989693164825, 0.0983898788690567, 0.029151055961847305, 0.048591531813144684, -0.11885503679513931, 0.04395979642868042, -0.1308152824640274, 0.3181397318840027, 0.01794976368546486, 0.1769695281982422, -0.06858950853347778, 0.14465731382369995, 0.14704042673110962, -0.01926078088581562, 0.019381189718842506, 0.04155753180384636, 0.008256982080638409, 0.024032987654209137, 0.10001535713672638, 0.08270082622766495, -0.013529861345887184, 0.03650787100195885, 0.06269856542348862, 0.012104436755180359, 0.07351955771446228, 0.013913425616919994, -0.02391667291522026, -0.04737363010644913, 0.08165077865123749, 0.08895079046487808, 0.0733938217163086, -0.0016540074720978737, 0.012732094153761864, -0.05668162554502487, 0.061139561235904694, 0.13663515448570251, -0.11837968975305557, -1.0847893863561996e-32, 0.024595625698566437, -0.07077624648809433, -0.0567191019654274, -0.028509436175227165, -0.12130428850650787, -0.05135306343436241, 0.17446750402450562, 0.07250738888978958, -0.03531220555305481, -0.1722276657819748, -0.07850366830825806, 0.12083940207958221, 0.07571117579936981, 0.030387239530682564, -0.14341264963150024, -0.0741676390171051, -0.005027772858738899, -0.17916032671928406, 0.0972772091627121, -0.08299223333597183, 0.06331890821456909, 0.0740436539053917, -0.11683675646781921, 0.1544501930475235, 0.0354708656668663, 0.03296263515949249, -0.0354156531393528, 0.06892404705286026, -0.1867237389087677, 0.027018144726753235, -0.06174962967634201, -0.07084845006465912, -0.1051618829369545, 0.14321035146713257, 0.08325526118278503, -0.02588766999542713, 0.053240515291690826, -0.12309558689594269, -0.007075021043419838, 0.07902294397354126, 0.08938158303499222, -0.016664402559399605, 0.024972178041934967, -0.010481705889105797, -0.0451812744140625, -0.04592201113700867, 0.018976405262947083, 0.052935171872377396, 0.08633862435817719, -0.06920135021209717, -0.028074871748685837, 0.08111537247896194, -0.04157942533493042, 0.00210596714168787, -0.1348397582769394, 0.10744934529066086, 0.09800536930561066, 0.030656762421131134, -0.07359538972377777, -0.05247427895665169, -0.016430363059043884, 0.10733452439308167, 0.1484130173921585, -0.02620665729045868, 0.03775713965296745, 0.07334166765213013, -0.021648988127708435, -0.08762698620557785, -0.005655325949192047, -0.07168895751237869, 0.1250043660402298, -0.15743157267570496, 0.04886847734451294, -0.08003813773393631, -0.03600563108921051, 0.23235100507736206, 0.03100750967860222, -0.04344955459237099, -0.07181796431541443, 0.06385046243667603, -0.017252955585718155, 0.07427166402339935, -0.11896588653326035, -0.006482018157839775, -0.0743960589170456, 0.06267742067575455, 0.004275559447705746, -0.026197493076324463, -0.03584391996264458, 0.0005771573632955551, -0.20140136778354645, -0.10597692430019379, -0.04078003019094467, 0.13620692491531372, -0.0016285916790366173, -9.99018539005192e-08, 0.07947647571563721, -0.031026728451251984, 0.022998817265033722, 0.0019652945920825005, -0.02445550076663494, 0.057921167463064194, -0.020865317434072495, -0.09522852301597595, 0.16135665774345398, 0.22373273968696594, 0.12183225899934769, 0.172339528799057, -0.11757542192935944, 0.030323710292577744, -0.0834321528673172, 0.1244017630815506, -0.10370172560214996, -0.004156897775828838, -0.055857524275779724, -0.07418559491634369, 0.012246839702129364, 0.050398170948028564, 0.08154690265655518, 0.07302035391330719, 0.05912453681230545, -0.1264452487230301, -0.05865907296538353, 0.09910783916711807, -0.007076912559568882, 0.06885632872581482, -0.06985102593898773, -0.09993843734264374, 0.024395469576120377, -0.015641415491700172, 0.08538263291120529, 0.06738896667957306, 0.01171133667230606, 0.051556311547756195, 0.1139570027589798, 0.016285013407468796, 0.06552155315876007, -0.09490293264389038, -0.039438098669052124, -0.047378722578287125, -0.07416951656341553, -0.19646787643432617, -0.09265998750925064, 0.04646597430109978, 0.2111329734325409, -0.04519473761320114, -0.08506735414266586, -0.0021473513916134834, -0.02961491234600544, 0.0726451724767685, 0.09184863418340683, 0.06005043536424637, -0.12495923787355423, 0.02854592353105545, -0.15297523140907288, 0.02281225100159645, -0.046013955026865005, -0.15635515749454498, -0.010131355375051498, 0.13727614283561707], "changes": {"1wk": -5.4810527986365845}}, {"text": "LIVE The latest news and updates on Trump's tariffs Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio Agios Pharmaceuticals, Inc. Mon, Jan 13, 2025, 3:00 PM 10 min read In This Article: AGIO -2.25% Agios Pharmaceuticals, Inc. \u2013 FDA Accepted Agios\u2019 Supplemental New Drug Application for PYRUKYND \u00ae (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia; PDUFA Goal Date is September 7, 2025 \u2013 \u2013 Topline Results from Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease to be Announced in Late 2025, with Potential U.S. Commercial Launch in 2026 \u2013 \u2013\u00a0Strong Financial Position Provides Opportunity to Maximize Potential PYRUKYND Commercial Launches, Advance Early- and Mid-Stage Clinical Programs and Expand Pipeline \u2013 CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced its anticipated key 2025 milestones and value-driving catalysts through 2026. The company\u2019s management team will present this information at the 43 rd Annual\u00a0J.P. Morgan Healthcare Conference\u00a0on\u00a0Wednesday, January 15, 2025, at\u00a07:30 a.m. PT / 10:30 a.m. ET. \u201c2024 was marked by exceptional progress at Agios. We delivered on all our key priorities, advanced our potential best- and first-in-class rare disease pipeline and further strengthened our financial position. Today, we are entering an era of growth and expansion for the company, building on a strong foundation and focus, and are well-positioned for a sustained trajectory of success,\u201d said\u00a0Brian Goff, chief executive officer at Agios. \u201cOur blueprint encompasses the potential for two additional commercial launches of PYRUKYND in thalassemia and sickle cell disease in 2025 and 2026, respectively, along with an early- and mid-stage pipeline that offers a strong foundation for innovation and growth, all supported by a highly experienced team with proven executional excellence and a strong balance sheet. Over the next 12 months, our priorities will be to maximize the potential of the PYRUKYND franchise, advance and diversify our key pipeline programs, and strategically focus our capital deployment to sustain our growth. We are excited about the future and the meaningful impact we can have in addressing the critical needs of rare disease patients.\u201d 2024 Highlights: Thalassemia: Presented positive results from the ENERGIZE and ENERGIZE-T Phase 3 trials evaluating mitapivat versus placebo in adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, respectively. The ENERGIZE randomized clinical trial results\u00a0were presented at the European Hematology Association\u00a02024 Hybrid Congress in June 2024, and the ENERGIZE-T randomized clinical trial results\u00a0were presented at the 66 th American Society of Hematology Annual Meeting and Exposition in December 2024. Agios filed regulatory applications for mitapivat (PYRUKYND) for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia with the\u00a0U.S.,\u00a0European Union,\u00a0Kingdom of Saudi Arabia\u00a0and\u00a0United Arab Emirates\u00a0health authorities. Sickle Cell Disease: Completed enrollment of the Phase 3 RISE UP study that is evaluating mitapivat in sickle cell disease patients who are 16 years of age or older. This Phase 3 study enrolled more than 200 patients worldwide. Pediatric Pyruvate Kinase (PK) Deficiency: Reported topline results from the Phase 3 ACTIVATE-KidsT trial of mitapivat in children with PK deficiency who are regularly transfused. Further, completed enrollment of the Phase 3 ACTIVATE-Kids study of mitapivat in children with PK deficiency who are not regularly transfused. Lower-Risk Myelodysplastic Syndromes (LR-MDS): Initiated patient enrollment in the Phase 2b study of tebapivat (AG-946) in LR-MDS. Additionally, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to tebapivat for the treatment of MDS. Early-Stage Pipeline :\u00a0Dosed the first healthy volunteer participants in the Phase 1 study of AG-181, a PAH stabilizer, in phenylketonuria. Corporate Development : Announced a\u00a0$905 million\u00a0purchase agreement with Royalty Pharma for Agios\u2019 rights to its vorasidenib royalty. Under the agreement, Agios received a payment of\u00a0$905 million\u00a0following the approval of vorasidenib by the FDA. Royalty Pharma will receive the entirety of the 15% royalty on annual\u00a0U.S.\u00a0net sales of vorasidenib up to\u00a0$1 billion, and a 12% royalty on annual\u00a0U.S.\u00a0net sales greater than\u00a0$1 billion. Agios retains a 3% royalty on annual\u00a0U.S.\u00a0net sales greater than\u00a0$1 billion. Agios also received a\u00a0$200 million\u00a0milestone payment from\u00a0Servier\u00a0following the FDA approval of vorasidenib. Altogether, Agios received a total of $1.1 billion\u00a0in milestone payments as part of this purchase agreement. Entered into a distribution agreement with\u00a0NewBridge Pharmaceuticals\u00a0to advance commercialization of PYRUKYND in the\u00a0Gulf Cooperation Council\u00a0(GCC) region. NewBridge, a leading specialty company headquartered in\u00a0Dubai, will commercialize PYRUKYND in\u00a0Bahrain,\u00a0Kuwait,\u00a0Oman,\u00a0Qatar,\u00a0Saudi Arabia\u00a0and the United Arab Emirates. Story Continues Anticipated 2025 Milestones: Thalassemia: Receive FDA regulatory decision for PYRUKYND for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The review classification for the company\u2019s supplemental New Drug Application is Standard and the Prescription Drug User Fee Act (PDUFA) goal date is\u00a0September 7, 2025. Sickle Cell Disease : Announce topline results from the Phase 3 RISE UP study of mitapivat in sickle cell disease in late 2025, with a potential U.S. commercial launch in 2026. Additionally, begin patient enrollment for the Phase 2 study of tebapivat in sickle cell disease in mid-2025. Pediatric Pyruvate Kinase (PK) Deficiency: Announce topline results from the Phase 3 ACTIVATE-Kids study of mitapivat in children with PK deficiency who are not regularly transfused in early 2025. Lower-Risk Myelodysplastic Syndromes (LR-MDS): Complete patient enrollment in the Phase 2b study of tebapivat for LR-MDS in late 2025. Early-Stage Pipeline: File an Investigational New Drug Application for AG-236, a siRNA targeting TMPRSS6 intended for the treatment of polycythemia vera, in mid-2025. Presentation at 43 rd Annual J.P. Morgan Healthcare Conference Agios\u2019 management team will present at the 43 rd Annual\u00a0J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET. The live webcast will be accessible on the Investors section of the company's website ( www.agios.com ) under the \u201cEvents & Presentations\u201d tab. A replay of the webcast will be archived on the company\u2019s website for at least two weeks following the presentation. About PYRUKYND \u00ae (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. U.S. IMPORTANT SAFETY INFORMATION Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath. Hepatocellular Injury in Another Condition: In patients with another condition treated with PYRUKYND at a higher dose than that recommended for patients with PK deficiency, liver injury has been observed. These events were characterized by a time to onset within the first 6 months of treatment with peak elevations of alanine aminotransferase of >5\u00d7 upper limit of normal (ULN) with or without jaundice. All patients discontinued treatment with PYRUKYND, and these events improved upon treatment discontinuation. Obtain liver tests prior to the initiation of PYRUKYND and monthly thereafter for the first 6 months and as clinically indicated. Interrupt PYRUKYND if clinically significant increases in liver tests are observed or alanine aminotransferase is >5x ULN. Discontinue PYRUKYND if hepatic injury due to PYRUKYND is suspected. Adverse Reactions: The most common adverse reactions including laboratory abnormalities (\u226510%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia. Drug Interactions: Strong CYP3A Inhibitors and Inducers: Avoid concomitant use. Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily. Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage. Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index. UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index. P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index. Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment. Please see full Prescribing Information for PYRUKYND. About Agios Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndrome (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company\u2019s website at www.agios.com . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of PYRUKYND \u00ae (mitapivat), tebapivat (AG-946), AG-236 and AG-181, Agios\u2019 PAH stabilizer; Agios\u2019 plans, strategies and expectations for its preclinical, clinical and commercial advancement of its drug development, including PYRUKYND \u00ae , tebapivat, AG-181 and AG-236; the submission of PYRUKYND \u00ae to regulators for approval in alpha-and-beta thalassemia; Agios\u2019 strategic vision and goals, including its key milestones for 2025; and the potential benefits of Agios\u2019 strategic plans and focus. The words \u201canticipate\u201d, \u201cexpect\u201d, \u201cgoal\u201d, \u201chope\u201d, \u201cmilestone\u201d, \u201copportunity\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201cpossible\u201d, \u201cstrategy\u201d, \u201cwill\u201d, \u201cvision\u201d, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios\u2019 current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios\u2019 product candidates will successfully continue. There can be no guarantee that any positive developments in Agios\u2019 business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios\u2019 business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios\u2019 results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios\u2019 ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios\u2019 ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of AG-236, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios\u2019 cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption \"Risk Factors\" included in Agios\u2019 public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contacts: Investor Contact Chris Taylor, VP, Investor Relations and Corporate Communications Agios Pharmaceuticals IR@agios.com Media Contact Eamonn Nolan, Senior Director, Corporate Communications Agios Pharmaceuticals Media@agios.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AGIO", "date": "2025-01-13T15:00:00", "sentiment": {"score": 0.910610674880445, "confidence": 0.9199513792991638, "probabilities": {"positive": 0.9199513792991638, "negative": 0.009340704418718815, "neutral": 0.07070788741111755}}, "embedding": [-0.2350156605243683, -0.1038963720202446, -0.0290304534137249, -0.08858423680067062, 0.08165213465690613, -0.05153384804725647, -0.1107625812292099, 0.2688762843608856, 0.054050739854574203, 0.00848848931491375, -0.08569465577602386, 0.13520562648773193, -0.07651079446077347, 0.0023621059954166412, -0.06261321902275085, 0.029812484979629517, -0.06162331998348236, 0.019078794866800308, -0.1633463203907013, -0.052261438220739365, 0.00819995068013668, -0.0019407984800636768, 0.04358534514904022, 0.0019327937625348568, -0.0636460930109024, 0.023298216983675957, -0.023172175511717796, -0.06477513909339905, -0.20933373272418976, 0.005824996158480644, -0.07462678849697113, 0.11128280311822891, 0.009028255939483643, -0.0041027190163731575, -0.004021211061626673, 0.12142115831375122, -0.14507651329040527, -0.00183107890188694, -0.023663995787501335, -0.20766009390354156, 0.15603366494178772, -0.20231875777244568, -0.10905694961547852, 0.11240046471357346, -0.014785900712013245, -0.1265152394771576, -0.09090767800807953, -0.025320125743746758, 0.04740861803293228, 0.13389372825622559, -0.21994271874427795, -0.0742940753698349, -0.025039678439497948, -0.010017241351306438, -0.10509598255157471, 0.07969999313354492, -0.12434279918670654, -0.15993225574493408, -0.08417889475822449, -0.015913143754005432, -0.04420069232583046, -0.1369631290435791, -0.023076960816979408, 0.012032907456159592, 0.15987704694271088, 0.00915195420384407, 0.06104195863008499, -0.025572940707206726, -0.015101417899131775, -0.014507112093269825, 0.09033289551734924, -0.025904513895511627, 0.057117559015750885, 0.06741649657487869, 0.04635123908519745, 0.20487567782402039, 0.11798125505447388, 0.1173601895570755, 0.1376105397939682, -0.0967327207326889, 0.12210776656866074, 0.0641603171825409, 0.1166030764579773, 0.026435179635882378, -0.09808651357889175, 0.0439206101000309, -0.04707012325525284, 0.15103255212306976, 0.02330869436264038, 0.014146171510219574, 0.07589547336101532, 0.029008915647864342, -0.056032925844192505, 0.06427815556526184, -0.1312662661075592, 0.07567949593067169, 0.004871394485235214, -0.07872365415096283, 0.04782675951719284, 0.07830467075109482, 0.0028714381624013186, 0.06212741136550903, -0.06372576951980591, -0.07681278884410858, -0.07791411876678467, -0.1289791762828827, 0.002156042493879795, -0.09503304958343506, 0.0649404227733612, -0.03342100977897644, -0.0528835654258728, 0.035280026495456696, 0.027944155037403107, -0.07089491188526154, -0.12079933285713196, 0.18267762660980225, -0.07111448049545288, -0.08027534186840057, 0.12419691681861877, -0.01343859639018774, 0.07063367962837219, 0.06788620352745056, -0.06519602239131927, 0.012752899900078773, 0.021497076377272606, -0.04857957363128662, -0.1597513109445572, 6.386751742869317e-33, -0.057848043739795685, 0.07882744073867798, 0.14580653607845306, 0.09149473905563354, -0.04944852739572525, -0.013335984200239182, 0.05939224362373352, -0.1755230724811554, -0.19184914231300354, -0.010132749564945698, -0.19462370872497559, -0.014849526807665825, -0.006983036641031504, 0.07291731983423233, -0.17503070831298828, -0.234694242477417, -0.047434285283088684, 0.048700641840696335, 0.06466959416866302, 0.008715278469026089, 0.10415025055408478, -0.03029712289571762, -0.023359820246696472, 0.014855485409498215, 0.04624047130346298, 0.1435880810022354, 0.013470481149852276, 0.03311265632510185, 0.05985541641712189, 0.07368172705173492, -0.08958343416452408, 0.09053122997283936, -0.04697433486580849, -0.1344832181930542, -0.15289831161499023, -0.04281344637274742, -0.29030442237854004, -0.15833893418312073, 0.016056280583143234, 0.102906733751297, -0.06584544479846954, 0.11595606803894043, -0.19027909636497498, 0.006739571690559387, 0.06445744633674622, -0.0715012401342392, -0.027142424136400223, 0.08644288033246994, 0.04029501974582672, -0.08756083250045776, -0.036880023777484894, -0.07474620640277863, 0.02581603266298771, -0.08593640476465225, 0.047554947435855865, -0.0713081806898117, -0.11596964299678802, -0.11304056644439697, 0.0830363929271698, 0.08332329243421555, 0.21210739016532898, 0.07964323461055756, -0.11688278615474701, 0.07931593060493469, -0.13530702888965607, 0.1326049268245697, -0.036769330501556396, 0.01895534247159958, -0.07643076777458191, 0.16967669129371643, 0.09280388057231903, -0.0017458004876971245, 0.09238135814666748, -0.052029870450496674, 0.08132176101207733, -0.001133328303694725, 0.1472097635269165, 0.07900118827819824, 0.02794273942708969, 0.08198113739490509, 0.02051088586449623, 0.04089772328734398, -0.07029992341995239, 0.15885239839553833, -0.07148383557796478, -0.007265985012054443, -0.020031407475471497, 0.02035626582801342, -0.09559164941310883, 0.009718306362628937, 0.15803223848342896, -0.08596701920032501, -0.05737558752298355, 0.15256854891777039, 0.026910630986094475, -7.551052448735899e-33, 0.12147394567728043, 0.0471743643283844, -0.04296063631772995, -0.11470715701580048, 0.040841054171323776, 0.0182588379830122, 0.14709928631782532, 0.04120199754834175, 0.07389995455741882, 0.02019345387816429, 0.07737452536821365, 0.13962578773498535, 0.018873270601034164, -0.05689181387424469, -0.0863187238574028, 0.02025546319782734, 0.09643131494522095, -0.13360707461833954, -0.005479566287249327, 0.11347655951976776, 0.029550494626164436, 0.2595672011375427, -0.18837139010429382, 0.13105326890945435, 0.001860451651737094, 0.05422729626297951, 0.03874235227704048, 0.12070829421281815, -0.017479252070188522, -0.10628153383731842, -0.07854059338569641, 0.008875871077179909, -0.21346910297870636, 0.03306323289871216, 0.05328160896897316, -0.02951173670589924, 0.0938459113240242, -0.15234872698783875, 0.003966435324400663, -0.028680583462119102, 0.08295125514268875, -0.004687313921749592, -0.05271109938621521, 0.09471014142036438, 0.09265530109405518, 0.06432193517684937, 0.011024083942174911, 0.007256445474922657, 0.1501878947019577, -0.0569281131029129, -0.04069828987121582, 0.1021171510219574, -0.07007326185703278, 0.009953413158655167, -0.058128826320171356, 0.07088611274957657, 0.01751408725976944, -0.10214947909116745, -0.05382734537124634, 0.004144624341279268, -0.029629647731781006, -0.017368335276842117, 0.08648420870304108, -0.022138433530926704, 0.00315852090716362, 0.10792684555053711, 0.1038740947842598, -0.0013974523171782494, -0.041589658707380295, 0.04983587563037872, -0.004790066741406918, 0.007376760710030794, -0.15103048086166382, -0.1545288860797882, -0.023542633280158043, 0.08921928703784943, 0.016769476234912872, 0.007079480215907097, -0.09725140035152435, 0.007105576805770397, -0.037089716643095016, 0.0015397462993860245, -0.09651648998260498, 0.04817342758178711, 0.11702662706375122, 0.029625874012708664, 0.13622571527957916, 0.04494372755289078, -0.012867800891399384, -0.005028421059250832, -0.10320436954498291, -0.164494127035141, -0.13419660925865173, 0.20616528391838074, 0.049536146223545074, -1.0047188681028274e-07, 0.1421200931072235, 0.047569673508405685, -0.06965628266334534, -0.06289844959974289, 0.007993822917342186, -0.03663164749741554, -0.05347341299057007, 0.06670543551445007, 0.1214703619480133, 0.16660866141319275, -0.02663881704211235, 0.20366548001766205, -0.014859435148537159, -0.05051848292350769, 0.06254657357931137, 0.11218592524528503, -0.1234031617641449, 0.05102923512458801, -0.06612726300954819, -0.1359097957611084, -0.08971337974071503, 0.07661851495504379, 0.03031400963664055, -0.05810437723994255, 0.014302210882306099, -0.050599802285432816, 0.046309687197208405, -0.011158255860209465, 0.030953537672758102, -0.1378074735403061, -0.03106733411550522, -0.021218828856945038, -0.007729877717792988, 0.0018667234107851982, 0.013332286849617958, -0.059354230761528015, -0.016706030815839767, 0.05799165368080139, 0.17064276337623596, 0.011865725740790367, 0.002314342651516199, 0.03947301208972931, -0.04410655423998833, 0.04943101853132248, -0.09564182162284851, -0.11266902089118958, -0.15725277364253998, -0.06460262835025787, 0.06624510884284973, -0.04906684532761574, -0.05271109566092491, 0.0363568514585495, -0.09000895172357559, 0.009685277007520199, 0.06392115354537964, 0.21292228996753693, -0.06328999996185303, -0.059127263724803925, -0.10600264370441437, -0.035936541855335236, 0.19241830706596375, -0.27143990993499756, 0.04313886538147926, 0.0864262729883194], "changes": {"1wk": -5.4810527986365845}}, {"text": "LIVE The latest news and updates on Trump's tariffs PREMIUM Agios Pharmaceuticals Says FDA Accepted Supplemental New Drug Application for Pyrukynd MT Newswires Wed, Jan 8, 2025, 7:16 PM In This Article: AGIO -2.25% Agios Pharmaceuticals (AGIO) said Wednesday that the US Food and Drug Administration has accepted fo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AGIO", "date": "2025-01-08T19:16:52", "sentiment": {"score": 0.11221704911440611, "confidence": 0.12128808349370956, "probabilities": {"positive": 0.12128808349370956, "negative": 0.009071034379303455, "neutral": 0.8696408867835999}}, "embedding": [-0.15149691700935364, -0.12609216570854187, 0.024882154539227486, -0.008905749768018723, 0.2905174791812897, -0.10169126838445663, -0.0588446669280529, 0.2259308099746704, -0.10495185852050781, -0.02988284081220627, -0.009454832412302494, 0.20544695854187012, -0.11639157682657242, 0.03616608679294586, 0.10905726999044418, -0.026639048010110855, 0.16357596218585968, 0.009928961284458637, -0.049103714525699615, 0.07259971648454666, -0.035789694637060165, -0.04669666662812233, 0.07438743114471436, 0.04206594079732895, -0.014093046076595783, 0.025636833161115646, -0.1150568276643753, 0.06260813772678375, -0.06108398735523224, 0.028445225208997726, -0.08969438821077347, -0.024111995473504066, 0.13619635999202728, -0.04981052130460739, 0.060075849294662476, -0.0417330339550972, -0.10302549600601196, -0.003502926090732217, 0.028025509789586067, -0.132601797580719, 0.24994175136089325, -0.256676584482193, -0.09126202762126923, 0.12652337551116943, -0.018664229661226273, -0.16072410345077515, -0.08272430300712585, -0.03491611406207085, 0.06553191691637039, 0.10885410755872726, -0.09218534082174301, -0.12660148739814758, 0.03556220605969429, -0.0027456041425466537, -0.07028117030858994, -0.10021870583295822, -0.13599799573421478, -0.15768657624721527, -0.1364080309867859, -0.07213066518306732, -0.026651471853256226, -0.21594376862049103, -0.1282607465982437, 0.18747840821743011, 0.011805495247244835, 0.13398128747940063, -0.051989927887916565, -0.01200810819864273, 0.020072858780622482, -0.19043156504631042, 0.045521121472120285, 0.14447687566280365, 0.20775555074214935, -0.0026537207886576653, 0.11638344824314117, 0.14017818868160248, 0.11922819167375565, 0.0769900530576706, 0.1471734344959259, -0.17383654415607452, 0.13346251845359802, 0.046296875923871994, 0.12820711731910706, -0.0497787669301033, 0.007888632826507092, -0.01698497124016285, -0.09246471524238586, 0.029835589230060577, -0.09120657294988632, -0.09490364044904709, 0.22126877307891846, -0.047157399356365204, -0.11412787437438965, 0.004322165623307228, -0.20389525592327118, -0.021770499646663666, -0.1492742896080017, -0.1073136180639267, -0.1632550209760666, 0.07670322805643082, 0.0473628044128418, -0.019829126074910164, -0.11218540370464325, 0.01628374680876732, -0.0672731027007103, -0.11115094274282455, -0.05698363482952118, 0.01467779278755188, -0.02628500573337078, 0.1864539533853531, -0.009964169934391975, 0.09248165041208267, 0.08905301243066788, -0.08247163891792297, -0.2194603532552719, 0.13266558945178986, -0.06643223017454147, -0.13231517374515533, 0.08810261636972427, -0.011229720897972584, -0.02326923981308937, 0.016702450811862946, -0.06385630369186401, 0.030127840116620064, 0.06977831572294235, -0.10304605215787888, -0.08938926458358765, 1.2377777720638126e-32, -0.12335879355669022, 0.17969611287117004, 0.12198758125305176, -0.15702366828918457, 0.046907659620046616, 0.05122338980436325, -0.017802052199840546, -0.2507729232311249, -0.18725302815437317, -0.10476759076118469, -0.2957656979560852, 0.22251540422439575, -0.046181969344615936, 0.13561734557151794, -0.08744987100362778, -0.16024820506572723, -0.020566018298268318, 0.18699297308921814, 0.3232761025428772, -0.009563857689499855, 0.1895434558391571, -0.10347649455070496, -0.04440036416053772, 0.057221341878175735, -0.07925251871347427, 0.2578071355819702, 0.05199405178427696, 0.019189903512597084, 0.059435222297906876, 0.10333296656608582, -0.12312527745962143, 0.07237136363983154, 0.01633826456964016, -0.025783078745007515, -0.02819041907787323, -0.037073273211717606, -0.18906833231449127, -0.1030624583363533, -0.06567584723234177, -0.15163087844848633, 0.02028598263859749, 0.0770668312907219, -0.12994420528411865, 0.15085682272911072, 0.013509297743439674, -0.11877736449241638, -0.10332151502370834, 0.051906514912843704, 0.10451266169548035, -0.022836340591311455, -0.03157130628824234, -0.06674084067344666, -0.1261058747768402, -0.04592711851000786, 0.002247362630441785, -0.11011599749326706, -0.16761061549186707, -0.11913606524467468, 0.12915991246700287, -0.04417281597852707, 0.31240972876548767, 0.06516502052545547, -0.05102744698524475, -0.008559834212064743, -0.18224021792411804, 0.1428677886724472, -0.09915489703416824, -0.06542527675628662, -0.04893231764435768, 0.22223669290542603, 0.15267525613307953, 0.007441460620611906, -0.03082522563636303, 0.1604643166065216, -0.09231206029653549, 0.007052204571664333, 0.08989162743091583, -0.032645974308252335, 0.18373844027519226, 0.04801078885793686, 0.05574139580130577, -0.10033862292766571, -0.0060230945236980915, 0.19228661060333252, -0.1100776419043541, 0.10058929771184921, -0.12729133665561676, 0.018776144832372665, 0.10063337534666061, 0.10433907061815262, 0.044058334082365036, -0.07041074335575104, -0.10956478118896484, 0.13954728841781616, 0.0010903578950092196, -1.5009781571158215e-32, -0.02819952555000782, 0.0754987969994545, 0.018263107165694237, -0.0950840413570404, -0.15224717557430267, 0.008629740215837955, -0.012681001797318459, 0.16619664430618286, 0.3635174334049225, 0.12325207144021988, 0.07105948776006699, 0.11382564902305603, 0.024254681542515755, 0.0019664678256958723, -0.02699294500052929, 0.013636081479489803, -0.001134994556196034, -0.053816284984350204, 0.024976400658488274, 0.04846176132559776, -0.09127336740493774, 0.14233960211277008, -0.14718659222126007, 0.15867125988006592, 0.09208708256483078, -0.03701996058225632, 0.02106674760580063, 0.1661687195301056, -0.0915587991476059, -0.09242333471775055, -0.05455286428332329, -0.017644589766860008, -0.2949822247028351, 0.048322807997465134, -0.006127347704023123, -0.03467945009469986, 0.20981669425964355, 0.05872754752635956, -0.011238082312047482, 0.02651272714138031, 0.10655716806650162, -0.09473715722560883, -0.048797816038131714, 0.17665378749370575, 0.03772052377462387, -0.008328856900334358, -0.0907672792673111, -0.0358981192111969, 0.0720132514834404, -0.1479569673538208, -0.12437418103218079, 0.055685579776763916, 0.04822622984647751, -0.03536565974354744, -0.07508422434329987, 0.084596186876297, 0.08007531613111496, 0.038151152431964874, -0.09319594502449036, -0.048079513013362885, 0.05882441997528076, -0.03286343812942505, -0.16522790491580963, -0.11661593616008759, 0.06776782870292664, 0.0794053003191948, 0.06916444003582001, -0.055687058717012405, 0.023095522075891495, 0.17206162214279175, 0.010791072621941566, 0.0005178519641049206, -0.07749290764331818, -0.1458369642496109, 0.02420796826481819, 0.19322848320007324, 0.06079905107617378, -0.012005211785435677, -0.13397057354450226, -0.006597533356398344, 0.09023488312959671, -0.10109996050596237, -0.029033992439508438, 0.04511162266135216, -0.09036996215581894, -0.058609362691640854, 0.1884552538394928, -0.07991234958171844, -0.1277541071176529, -0.019501587375998497, -0.13050858676433563, -0.022361479699611664, -0.1776149868965149, 0.14433908462524414, 0.016151905059814453, -1.0077862810931038e-07, 0.15273645520210266, -0.08359116315841675, -0.05518423765897751, 0.09733948856592178, 0.025864912196993828, 0.06842375546693802, -0.15079905092716217, -0.09040845930576324, 0.016505364328622818, 0.07742337137460709, -0.12416781485080719, 0.11108032613992691, 0.027203300967812538, -0.13205097615718842, -0.02503393590450287, 0.0640939399600029, 0.1293562799692154, 0.09189441800117493, -0.05102808028459549, -0.07406488806009293, -0.15769794583320618, 0.16093985736370087, 0.04554477334022522, -0.11053532361984253, 0.02627035602927208, 0.009513304568827152, 0.007270248141139746, -0.13203996419906616, 0.03688562661409378, 0.009949273429811, 0.024290168657898903, -0.028351815417408943, -0.05069024860858917, 0.040379688143730164, -0.01793612539768219, -0.005736749153584242, -0.060202889144420624, 0.07578681409358978, 0.10813763737678528, -0.10724839568138123, 0.036076031625270844, 0.024826401844620705, 0.018833396956324577, 0.025578977540135384, -0.07950838655233383, 0.05083678290247917, -0.17204144597053528, -0.16442061960697174, 0.14369234442710876, 0.02546822279691696, 0.10568497329950333, -0.03365024924278259, 0.09453689306974411, -0.12404076755046844, -1.718309795251116e-05, 0.08087969571352005, 0.0011558615369722247, -0.14556986093521118, -0.08149674534797668, -0.032153137028217316, 0.14589998126029968, -0.2712498903274536, 0.09199235588312149, 0.07534145563840866], "changes": {"1wk": -7.298057479728444}}, {"text": "LIVE The latest news and updates on Trump's tariffs New Large-Scale Mining, Metallurgical, and Industrial Investment by METLEN Amounting to \u20ac295.5 Million PR Newswire Thu, Jan 16, 2025, 12:43 PM 4 min read Development of an Integrated Production Line for Bauxite, Alumina, and Gallium Investment Plan of \u20ac295.5 million Total Annual Production Capacity of1,265,000 tonnes of alumina, 50 MT of Gallium, and ~2 million tonnes of bauxite Full substitution of Gallium imports in Europe Improvement of Greece's trade balance through increased exports ATHENS , Greece , Jan. 16, 2025 /PRNewswire/ -- METLEN Energy & Metals ( METLEN ) announces that the Metallurgy Committee, in a joint session with the Capital Allocation Committee, made the Final Investment Decision (FID) today, January 16, 2025 , to proceed with the implementation of a new large-scale investment in the production of bauxite, alumina, and Gallium. Metlen Logo (PRNewsfoto/Metlen Energy & Metals) This landmark project, to be implemented in Agios Nikolaos, Viotia, within the historic \"Aluminium of Greece \" plant, represents a milestone in the history of the Metallurgy Sector. It will significantly enhance the production capacity while incorporating Gallium into industrial production for the first time, a critical material for Europe's future. The \u20ac295.5 million investment plan aims to achieve a total production capacity of 2 million tonnes of bauxite (annually), 1,265,000 tonnes of alumina (up from 865,000 tonnes currently), and 50 MT of Gallium for the first time. All three materials are included in the European Union's list of Critical Raw Materials (CRMs). The total capital expenditure (Capex) includes the following investments: Development of research and new bauxite mining deposits, Construction of new facilities and procurement of mechanical equipment for Gallium production, New facilities and equipment for the expansion and modernization of alumina production capacity, Energy supply infrastructure for the industrial unit, Port expansion and upgrades, Other road infrastructure and flood protection projects, Evangelos Mytilineos, Chairman and CEO of METLEN, commented: \u00ab The decision by METLEN to proceed with the implementation of a new, landmark industrial investment in the production of bauxite, alumina and G allium, strengthens Europe's self-sufficiency in critical raw materials and bolsters Greece's strategic position on the global landscape. Moreover, it shields the European industry from external dependencies. We are proving our commitment to innovation, sustainable development, and circular economy, while reaffirming METLEN's role as a leader in the transition toward greener and more resilient industrial production . \u00bb Specifically for Gallium, it should be noted that it is a by-product of certain qualities of bauxite (including Greek bauxite) during the refining process into alumina, with its production being almost entirely concentrated in China . However, China's decision to impose export restrictions on Gallium ( July 2023 ) highlighted the West's vulnerability and the need to diversify supply sources. Story Continues METLEN's investment enables Europe to completely substitute Gallium imports, significantly bolstering its strategic autonomy and minimizing reliance on external suppliers. This autonomy is crucial for reducing dependence on third countries and ensuring the production of critical technologies across various sectors, from energy transition to defence. For instance, Gallium is essential for: a) Integrated Circuits (IC) used in computing and telecoms, b) Light emitting diodes (LED) and c) Permanent magnets etc. The production of these three critical materials\u2014valued at approximately \u20ac1 billion\u2014will be exported to European and North American markets. This state-of-the-art investment will also introduce new environmentally friendly technologies, reducing the facility's carbon footprint. In addition, through critical synergies with METLEN's Energy Sector, energy costs will become completely sustainable. METLEN has submitted the investment project under Greece's Strategic Investments Law. The investment also meets the criteria of the \"Temporary Crisis and Transition Framework\" (TCTF), aimed at supporting the economy in the aftermath of the Russian invasion of Ukraine . Furthermore, the project recently received the European Commission's STEP SEAL (so called \"Sovereignty Seal\"), recognizing its significant contribution to the EU's self-sufficiency in critical raw materials (CRM). METLEN is committed to keeping investors informed of the project's progress. Completion of the works and production start-up is scheduled for 2026 for bauxite, with alumina and Gallium production beginning gradually from 2027 and full-scale operation by 2028. METLEN: METLEN Energy & Metals \u2013 evolution of MYTILINEOS Energy & Metals - is a multinational industrial and energy company, a leader in the metallurgy and energy industries, focused on sustainability and circular economy. The Company is listed on the Athens Stock Exchange, with a consolidated turnover and EBITDA of \u20ac5.492 billion and \u20ac1.014 billion, respectively. METLEN is a reference point for competitive green metallurgy at the European and global level, whilst operating the only vertically integrated bauxite, alumina and primary aluminum production unit in the European Union (E.U.) with privately owned port facilities. In the energy sector, METLEN offers comprehensive solutions, covering thermal and renewable energy projects, electricity distribution and trading, alongside investments in grid infrastructure, \u00a0\u00a0battery storage, and other green technologies. The Company is active in the markets of all five continents, in 40 countries, adopting a full-scale synergetic model between the Metallurgy and Energy Sectors, while undertaking end-to-end development of major energy infrastructure projects. For more information, please visit: www.metlengroup.com | Facebook | Twitter | YouTube | LinkedIn If you no longer wish to receive Press Releases and Updates from METLEN, click here . Logo: https://mma.prnewswire.com/media/2430163/Metlen_Logo.jpg Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/new-large-scale-mining-metallurgical-and-industrial-investment-by-metlen-amounting-to-295-5-million-302353026.html SOURCE Metlen Energy & Metals View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AGIO", "date": "2025-01-16T12:43:00", "sentiment": {"score": 0.860468088183552, "confidence": 0.8680140972137451, "probabilities": {"positive": 0.8680140972137451, "negative": 0.0075460090301930904, "neutral": 0.12443981319665909}}, "embedding": [-0.10081791877746582, -0.05225367844104767, -0.06142468377947807, 0.059875261038541794, 0.06744417548179626, -0.16216900944709778, -0.016290482133626938, 0.08909772336483002, -0.1680867075920105, 0.016617421060800552, -0.1355765014886856, -0.1170378103852272, 0.045428529381752014, -0.04459404945373535, -0.10553203523159027, 0.014798459596931934, -0.019222600385546684, -0.06560052186250687, -0.18369649350643158, 0.13197851181030273, 0.23740819096565247, -0.08134323358535767, 0.009016233496367931, 0.013723143376410007, 0.08607254922389984, 0.1548357456922531, -0.05943148955702782, -0.05899412930011749, -0.13538533449172974, -0.04396776109933853, -0.04277876019477844, 0.22938552498817444, 0.03934600576758385, -0.054798148572444916, 0.03164840489625931, 0.04056047275662422, -0.09621047973632812, 0.025684090331196785, -0.09764263778924942, -0.13216784596443176, -0.08393923938274384, 0.04370340704917908, 0.03265921771526337, -0.002832838101312518, -0.13806112110614777, -0.029527176171541214, 0.05702584981918335, 0.030659407377243042, -0.017359616234898567, 0.02801964432001114, -0.07929441332817078, -0.11300906538963318, -0.046565454453229904, -0.08182443678379059, -0.09273960441350937, 0.0013712802901864052, -0.03424934297800064, -0.08346666395664215, 0.0033181135077029467, -0.000992577988654375, 0.008035133592784405, -0.09898754954338074, -0.026115838438272476, -0.06611470878124237, 0.19104254245758057, -0.01773642562329769, -0.1287713646888733, -0.12283346056938171, -0.15253017842769623, 0.025392837822437286, 0.1538103073835373, -0.13188321888446808, -0.08572615683078766, -0.10528646409511566, 0.0463021844625473, 0.23893624544143677, 0.2571297883987427, -0.00667639309540391, 0.07209689915180206, -0.1701168715953827, -0.024290449917316437, 0.18439264595508575, 0.010375410318374634, -0.14263902604579926, 0.0590825155377388, 0.05492916703224182, 0.10033254325389862, 0.05985163524746895, 0.11893312633037567, 0.02419055625796318, 0.13875529170036316, 0.023952089250087738, -0.13787448406219482, -0.008119446225464344, 0.08120754361152649, 0.12644225358963013, 0.008199755102396011, 0.1897887885570526, 0.0071729253977537155, 0.09206248819828033, 0.07376398146152496, 0.034182365983724594, 0.04581497982144356, -0.1000959575176239, -0.20535385608673096, -0.009169074706733227, 0.014468894340097904, 0.026192795485258102, -0.08027811348438263, 0.057141512632369995, 0.06552453339099884, -0.03922180086374283, -0.003133706748485565, -0.21307699382305145, -0.06257881224155426, 0.13742996752262115, -0.03834517300128937, -0.1667563021183014, 0.1491955816745758, -0.05880100652575493, 0.06983044743537903, 0.020341791212558746, -0.043386172503232956, 0.012758775614202023, 0.031013142317533493, 0.03169385343790054, -0.09208659082651138, 9.243784885071132e-33, -0.19126996397972107, -0.028401969000697136, -0.06588121503591537, 0.022713927552103996, -0.1403428316116333, 0.022728340700268745, 0.0018124179914593697, 0.06277698278427124, -0.06416018307209015, -0.19200322031974792, -0.13696511089801788, 0.2040981501340866, 0.037069644778966904, 0.012513967230916023, 0.08657648414373398, -0.24580118060112, 0.23196318745613098, -0.005138968117535114, 0.08332708477973938, -0.00031115952879190445, -0.014316515065729618, -0.14800459146499634, -0.013429388403892517, 0.12722298502922058, 0.08493155241012573, 0.18667685985565186, 0.08579495549201965, -0.11225879192352295, -0.15281066298484802, 0.053566835820674896, 0.07811951637268066, 0.12153057008981705, -0.047852110117673874, 0.04164718836545944, -0.16698190569877625, 0.04214978963136673, -0.16502735018730164, -0.08001068234443665, -0.10871376097202301, -0.08459199219942093, 0.04473850876092911, 0.0369524322450161, -0.006064371671527624, 0.1434118151664734, -0.013449104502797127, -0.04754703864455223, -0.052443329244852066, 0.1555238962173462, 0.0510961078107357, -0.03534265607595444, -0.009509285911917686, 0.12176557630300522, 0.01449638418853283, -0.1369456946849823, -0.06134733557701111, 0.06000550091266632, 0.006154859904199839, -0.0946890264749527, 0.15021908283233643, 0.08137106895446777, -0.0700950175523758, 0.1322900354862213, -0.010500716045498848, 0.2601235806941986, -0.04776538908481598, 0.2366195023059845, 0.026984376832842827, 0.13316093385219574, 0.023940179497003555, 0.021855641156435013, -0.06487758457660675, -0.09474178403615952, 0.20072051882743835, 0.11389172077178955, -0.04143594950437546, 0.14472077786922455, 0.1755199432373047, 0.0016430134419351816, -0.028354955837130547, 0.07274338603019714, -0.13687363266944885, 0.0668078362941742, -0.028270700946450233, -0.19345685839653015, -0.045475997030735016, -0.058442942798137665, -0.027931388467550278, 0.10737878084182739, 0.07176804542541504, -0.07622583210468292, 0.057087380439043045, -0.08316369354724884, -0.007590082008391619, 0.04890067130327225, -0.10268083214759827, -9.343553498729235e-33, 0.05314221233129501, 0.046771805733442307, 0.03379721939563751, -0.13362081348896027, -0.08618474751710892, 0.011510839685797691, -0.07966376841068268, -0.1549655795097351, -0.0341157466173172, -0.004269544035196304, 0.02173961140215397, -0.09680948406457901, 0.019207634031772614, -0.10523013770580292, -0.052098095417022705, 0.05502879619598389, 0.10268144309520721, -0.007771558593958616, -0.03250889480113983, -0.04029252380132675, 0.00832414161413908, 0.34815317392349243, -0.11187971383333206, 0.020688854157924652, -0.0932023823261261, -0.08414126932621002, -0.005394600331783295, -0.05208319053053856, 0.07506072521209717, -0.015259761363267899, -0.04663094878196716, -0.014236362650990486, -0.1650991439819336, 0.06759240478277206, -0.03030979447066784, -0.02940445765852928, 0.1331532597541809, -0.04802536219358444, 0.03851255774497986, 0.13032332062721252, 0.08245173841714859, 0.07515427470207214, -0.037401989102363586, 0.13873893022537231, 0.02982364594936371, -0.054735638201236725, -0.03618154674768448, -0.08430089056491852, 0.044274136424064636, -0.04001499339938164, 0.15972378849983215, 0.0004137260839343071, 0.010869973339140415, -0.1556251049041748, 0.02235286682844162, 0.12529462575912476, -0.07100647687911987, -0.0071538700722157955, -0.09199602901935577, -0.0044665210880339146, 0.09391631186008453, 0.07340147346258163, 0.1325863003730774, -0.03474131226539612, 0.05019295960664749, 0.02848556824028492, -0.12095145881175995, -0.017652029171586037, -0.03348472714424133, -0.012838253751397133, -0.04627181962132454, 0.15535703301429749, -0.058189693838357925, -0.00875169038772583, 0.0039182305335998535, 0.08106459677219391, 0.11074694991111755, 0.0260322242975235, -0.036624401807785034, 0.026414521038532257, 0.008541591465473175, 0.051006197929382324, 0.11394274234771729, -0.03128231316804886, 0.1370425671339035, -0.02433253452181816, -0.02502049319446087, -0.044319480657577515, 0.008424075320363045, 0.04987567290663719, -0.2363293170928955, -0.1011880487203598, 0.05537310242652893, 0.1818253993988037, 0.030915556475520134, -9.989302895974106e-08, -0.042176198214292526, 0.10161685943603516, 0.004046041518449783, 0.04273596405982971, 0.11669610440731049, -0.10837772488594055, -0.00028403010219335556, 0.04518118500709534, 0.01664550229907036, 0.12236019968986511, -0.1040407195687294, -0.01492791622877121, -0.07379227876663208, -0.061093248426914215, -0.06759807467460632, 0.159349724650383, -0.09143685549497604, 0.01972958631813526, -0.04174124449491501, -0.022798433899879456, 0.24427074193954468, -0.02762836217880249, 0.03458595648407936, 0.06107892096042633, -0.036938831210136414, -0.12441273033618927, 0.08961787819862366, 0.0633079782128334, -0.06840214133262634, 0.015381120145320892, -0.08580446243286133, -0.02123604528605938, 0.017507819458842278, -0.025283347815275192, 0.03075113333761692, -0.09118609875440598, 0.074283666908741, 0.04051213711500168, 0.04582216590642929, 0.094904825091362, -0.06942525506019592, -0.12250896543264389, 0.06899295747280121, -0.0366959311068058, -0.049811046570539474, -0.028152242302894592, -0.39201176166534424, -0.11558381468057632, 0.0953579768538475, -0.06342620402574539, -0.02502022497355938, 0.10616163909435272, 0.061395931988954544, 0.0807160884141922, 0.14616218209266663, 0.042616672813892365, 0.032805126160383224, -0.046307601034641266, -0.058735329657793045, 0.015480885282158852, 0.12167961895465851, -0.11171427369117737, 0.061370693147182465, -0.0027790814638137817], "changes": {"1wk": 7.039603079666752}}, {"text": "LIVE The latest news and updates on Trump's tariffs Disrupting Computational Biology: Elucidata's AI Revolutionizes Life Sciences PR Newswire Tue, Jan 14, 2025, 9:38 PM 6 min read AI is transforming healthcare, paving the way for breakthroughs in precision medicine and unlocking extraordinary value. On the Disruption Interruption podcast, Elucidata CEO Abhishek Jha discusses how a data-centric approach addresses life sciences' unique challenges. Discover the critical role of clean, structured data in driving AI-powered innovation and advancing the future of healthcare. TAMPA BAY, Fla. , Jan. 14, 2025 /PRNewswire-PRWeb/ -- AI has the potential to revolutionize healthcare, with McKinsey estimating it could unlock up to $1 trillion in value across the industry. (1) This week on the Disruption Interruption podcast, host Karla Jo Helms (KJ) explores this transformative frontier with Abhishek Jha , Co-Founder and CEO of Elucidata\u2014a biotech innovator at the intersection of AI and computational biology, driving advancements in precision medicine. Jha sheds light on the immense opportunities AI presents while addressing critical challenges the healthcare sector must overcome to fully harness its potential. \"The AI paradigm that worked for tech will not carry over to life sciences... it's time for data-centric AI,\" he asserts, emphasizing the need for a tailored approach to innovation in medicine. Computational Biology: Simulating Science, Accelerating Discovery Jha explains that computational biology allows researchers to simulate biological processes in the same way the aviation industry uses models to simulate flight conditions. \"You cannot test your plane in every condition; it's a very expensive and slow process,\" he notes. Similarly, researchers can test and refine models before applying them in real-world experiments, making the process more efficient. By iteratively refining these models based on experimental feedback, scientists can better understand intricate biological mechanisms. \"If the model is good, you can make some predictions, go back, and test it. If not, you improve your model,\" Jha illustrates. The Trillion-Dollar Problem: Bridging the Gap Between Tech and Life Sciences One of the most critical challenges between tech companies and life sciences is the sheer volume of data available. \"They think they have a trillion-dollar problem, but they have hundreds of ten-million-dollar problems,\" states Jha. As he explains, the entire paradigm must shift to adapt to a world where many valuable problems exist, rather than focusing on a singularly valuable one. Tech giants like Google benefit from access to billions of users generating data daily, providing them with an immense pool of information to fuel AI models. In contrast, life sciences data\u2014while equally critical\u2014remains far scarcer and harder to obtain. For instance, even large clinical trials for widespread conditions like breast cancer typically involve only a few thousand patients, a scale that pales in comparison to the vast data sources available to tech companies. Story Continues \"There's a significant disparity,\" Jha points out. \"How much data about my purchasing habits is available versus my health data? We don't have access to that, nor is it consolidated in one single place.\" Clean Data Over Big Data: The Key to AI Success Data cleaning and preparation are often underestimated in AI workflows, particularly in life sciences. Abhishek Jha compares this to \"technical debt,\" where rushing to amass data without proper structuring leads to long-term challenges. For instance, inconsistent terms like \"hepatitic carcinoma\" and \"liver cancer\" across datasets create inefficiencies, forcing researchers to spend months standardizing data before analysis. \"Clean data is always more valuable than more data,\" Jha emphasizes. \"Investing in a thoughtful data strategy is crucial for AI success.\" Without standardized terminology and organized datasets, life sciences risk delaying breakthroughs and limiting the potential of AI-driven innovation. Links Disrupting Drug Development Delays: How Abhishek Jha's Elucidata Is Powering Faster Medical Advances with AI https://omny.fm/shows/disruption-interruption/disrupting-drug-development-delays-how-abhishek-jh LinkedIn: https://www.linkedin.com/in/abhishek-jha-ba20a821/ Company Website: https://www.elucidata.io/ Disruption Interruption is the podcast where you will hear from today's biggest Industry Disruptors. Learn what motivated them to bring about innovation and how they overcame opposition to adoption. Disruption Interruption can be listened to in Apple's App Store and Spotify. About Disruption Interruption\u2122 Disruption is happening on an unprecedented scale, impacting all manner of industries\u2014 MedTech, Finance, IT, eCommerce, shipping, logistics, and more\u2014and COVID has moved their timelines up a full decade or more. But WHO are these disruptors and when did they say, \"THAT'S IT! I'VE HAD IT!\"? Time to Disrupt and Interrupt with host Karla Jo \"KJ\" Helms, veteran communications disruptor. KJ interviews badasses who are disrupting their industries and altering economic networks that have become antiquated with an establishment resistant to progress. She delves into uncovering secrets from industry rebels and quiet revolutionaries that uncover common traits\u2014and not-so-common\u2014that are changing our economic markets\u2026 and lives. Visit the world's key pioneers that persist to success, despite arrows in their backs at http://www.disruption-interruption.com . About Abhishek Jha Abhishek Jha is the Co-Founder and CEO of Elucidata, a trailblazing biotech company recognized as one of Fast Company's Most Innovative Biotech Companies of 2024. Under his leadership, Elucidata has transformed biological discovery by leveraging data-centric approaches and cutting-edge AI and ML innovations. Elucidata's flagship platform, Polly, accelerates research by harmonizing multi-modal biomedical data\u2014such as Omics, Assay, Real-World, Clinical, EHR, and CRO data\u2014into a Unified Data Model. Polly's LLM-powered curation enables 10x faster data preparation with 99.99% accuracy, drastically reducing the time to actionable insights and advancing precision medicine. Before founding Elucidata in 2015, Abhishek spent nearly six years as a Senior Scientist at Agios Pharmaceuticals, contributing to the development of four first-in-class drugs. His experience includes designing algorithms to integrate high-throughput metabolic data with transcriptional data and deploying visualization tools for clinical applications. Abhishek holds a Postdoctoral Fellowship from MIT , where he developed computational models in immunology, and his career has been defined by a passion for combining technology and science to revolutionize patient outcomes. Beyond his professional pursuits, Abhishek enjoys discussing innovations in biotech and mentoring the next generation of entrepreneurs. About Karla Jo Helms Karla Jo Helms is the Chief Evangelist and Anti-PR\u00ae Strategist for JOTO PR Disruptors\u2122. Karla Jo learned firsthand how unforgiving business can be when millions of dollars are on the line \u2014 and how the control of public opinion often determines whether one company is happily chosen, or another is brutally rejected. Being an alumnus of crisis management, Karla Jo has worked with litigation attorneys, private investigators, and the media to help restore companies of goodwill into the good graces of public opinion \u2014 Karla Jo operates on the ethic of getting it right the first time, not relying on second chances and doing what it takes to excel. Helms speaks globally on public relations, how the PR industry itself has lost its way, and how, in the right hands, corporations can harness the power of Anti-PR to drive markets and impact market perception. References 1. Bhasker, Shashank, et al. \"Tackling Healthcare's Biggest Burdens with Generative AI.\" mckinsey.com, 10 July 2023 , http://www.mckinsey.com/industries/healthcare/our-insights/tackling-healthcares-biggest-burdens-with-generative-ai . Media Inquiries: Karla Jo Helms JOTO PR\u2122 727-777-4629 Media Contact Karla Jo Helms , JOTO PR\u2122, 727-777-4629, khelms@jotopr.com , jotopr.com Cision View original content to download multimedia: https://www.prweb.com/releases/disrupting-computational-biology-elucidatas-ai-revolutionizes-life-sciences-302350601.html SOURCE Disruption Interruption View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AGIO", "date": "2025-01-14T21:38:00", "sentiment": {"score": 0.14696926064789295, "confidence": 0.16095829010009766, "probabilities": {"positive": 0.16095829010009766, "negative": 0.013989029452204704, "neutral": 0.8250526189804077}}, "embedding": [-0.13011658191680908, -0.041552118957042694, -0.06332452595233917, -0.003887410741299391, 0.10683734714984894, -0.14292320609092712, -0.08518379181623459, 0.06452477723360062, 0.07835683226585388, 0.10207753628492355, -0.1917441487312317, 0.040797073394060135, -0.00016683340072631836, 0.010495450347661972, -0.06350518763065338, 0.04390668123960495, -0.06848893314599991, -0.015539431944489479, -0.22375699877738953, 0.001812380738556385, 0.0611945316195488, 0.03219299018383026, 0.03965818136930466, -0.006243787705898285, -0.11437143385410309, -0.00889725610613823, 0.007917903363704681, -0.23493187129497528, -0.24708491563796997, 0.040633492171764374, 0.036958225071430206, 0.14237289130687714, -0.0503181517124176, -0.030634015798568726, -0.08181431889533997, 0.0723007470369339, -0.01684524118900299, 0.06720733642578125, 0.0897301733493805, 0.04495135694742203, -0.00042886100709438324, -0.05997402220964432, -0.0965835452079773, -0.011655173264443874, 0.18342852592468262, -0.13921253383159637, -0.05526000261306763, -0.06637860834598541, 0.05756703391671181, 0.10648452490568161, -0.363366961479187, -0.17104846239089966, 0.012885840609669685, 0.09457302838563919, 0.030551297590136528, 0.02637118473649025, 0.03680388629436493, 0.0288858599960804, -0.04707293212413788, 0.031140930950641632, 0.11755716055631638, -0.13988175988197327, 0.078168123960495, -0.00597281102091074, 0.1382424235343933, -0.08419525623321533, 0.05296796187758446, -0.016134630888700485, -0.045811161398887634, -0.01613515429198742, 0.08399498462677002, 0.05078785866498947, -0.06350553035736084, 0.10745416581630707, 0.1782514899969101, -0.024124596267938614, 0.12614938616752625, 0.15710529685020447, 0.2799125909805298, -0.09565266966819763, 0.0946522206068039, -0.12268689274787903, -0.09093962609767914, 0.0168836060911417, -0.11557474732398987, -0.06383484601974487, -0.04315665364265442, 0.06724809110164642, 0.0699201300740242, -0.06101437658071518, -0.033396270126104355, -0.1440110057592392, -0.03960954025387764, 0.008295862004160881, -0.0001511313021183014, 0.09761939942836761, -0.051813043653964996, 0.018803492188453674, -0.026340194046497345, 0.019151469692587852, -0.05447382479906082, 0.03464530035853386, 0.07591979205608368, -0.0710357055068016, -0.06090014800429344, -0.08170185983181, 0.06881040334701538, 0.0689762681722641, 0.11250939220190048, 0.019837772473692894, 0.012705839239060879, 0.06440621614456177, 0.11214382946491241, -0.032248057425022125, 0.06260950118303299, 0.1002444177865982, -0.027948690578341484, 0.02758939564228058, 0.09696526825428009, 0.006107786670327187, -0.01329791359603405, -0.010074224323034286, -0.029141630977392197, -0.08309108763933182, 0.10206527262926102, 0.08391037583351135, -0.17078787088394165, 6.1020290113429115e-33, -0.019468355923891068, 0.01790802925825119, 0.2167655974626541, 0.04329583793878555, 0.02575584128499031, -0.149183988571167, -0.02320811152458191, -0.02465110644698143, -0.031405258923769, -0.07661322504281998, -0.14258334040641785, 0.18001267313957214, -0.03570897877216339, 0.03161738067865372, 0.08631937950849533, -0.1183781623840332, -0.15137960016727448, -0.018547423183918, -0.04020208865404129, 0.0044723208993673325, 0.15038634836673737, -0.16981911659240723, -0.03968294337391853, -0.03207242861390114, 0.009520943276584148, 0.08519572019577026, 0.02548731304705143, -0.11059458553791046, 0.062070369720458984, 0.09045302867889404, -0.16935142874717712, 0.22351796925067902, -0.052406758069992065, -0.05695956572890282, 0.017441481351852417, -0.05648358166217804, -0.04735451936721802, -0.15188853442668915, -0.014611560851335526, 0.06811903417110443, -0.08817034959793091, 0.11039663851261139, 0.055990710854530334, -0.022130470722913742, 0.0058400677517056465, -0.032171182334423065, 0.08320365101099014, 0.10362796485424042, 0.08433350920677185, -0.07641410082578659, -0.042267799377441406, 0.03439469262957573, 0.07152959704399109, -0.15527836978435516, -0.01401554886251688, 0.06695521622896194, -0.03258505091071129, -0.07308723777532578, 0.10724550485610962, 0.17499662935733795, 0.018697787076234818, 0.03159118816256523, -0.03284770995378494, 0.24296694993972778, 0.003692157566547394, 0.08278607577085495, -0.05680527165532112, 0.04784464091062546, 0.046969421207904816, 0.17005038261413574, -0.05815731734037399, 0.022703342139720917, -0.014619752764701843, -0.09259612113237381, -0.04335695505142212, -0.04749247059226036, 0.003213520161807537, -0.10209403187036514, -0.031760942190885544, 0.029731428250670433, -0.012735782191157341, 0.03519025444984436, -0.07329263538122177, -0.029280735179781914, 0.03772468864917755, -0.020176634192466736, -0.03541428595781326, 0.06801685690879822, -0.09438013285398483, -0.09305112808942795, -0.03712988644838333, 0.023426087573170662, 0.09226015210151672, 0.021807994693517685, -0.04757292941212654, -7.284193925264131e-33, -0.12322226911783218, -0.10084614157676697, -0.17620697617530823, 0.1524081826210022, 0.21388626098632812, 0.01924138143658638, 0.08528707921504974, -0.11844167113304138, 0.03707553818821907, -0.1401723325252533, -0.01332993432879448, -0.02436724863946438, -0.010049713775515556, 0.06545540690422058, 0.04796455055475235, -0.05396842584013939, -0.09425601363182068, -0.13117268681526184, -0.09321103990077972, 0.07253970950841904, 0.07114846259355545, 0.12696224451065063, -0.21328309178352356, 0.029679015278816223, 0.025598280131816864, 0.06066448986530304, -0.10115215927362442, 0.19181644916534424, 0.08683402091264725, -0.009696952067315578, -0.1069655567407608, -0.03128105029463768, -0.19818860292434692, 0.03337835147976875, 0.028086109086871147, 0.09861069172620773, 0.08331983536481857, -0.14551383256912231, 0.0732751190662384, -0.10288117825984955, 0.15430031716823578, -0.01467854529619217, -0.31557339429855347, -0.024441491812467575, 0.11277617514133453, -0.002908477559685707, -0.17781928181648254, 0.0482795424759388, 0.013567603193223476, -0.05653531476855278, 0.10253484547138214, 0.03683001175522804, -0.04813056439161301, -0.11404508352279663, -0.07014959305524826, -0.0015691928565502167, -0.12506744265556335, 0.051254600286483765, 0.005541092716157436, 0.06967137008905411, -0.13186931610107422, 0.020673859864473343, 0.10648658871650696, 0.17331835627555847, -0.07260377705097198, 0.0657762959599495, 0.15638716518878937, 0.10206398367881775, -0.08375765383243561, -0.10434062778949738, 0.0229980256408453, 0.0020381025969982147, -0.03470714017748833, -0.03501713275909424, -0.04170119762420654, 0.09351605176925659, -0.11785770207643509, -0.045115672051906586, -0.12988734245300293, 0.05199884995818138, 0.09728876501321793, -0.12150217592716217, 0.08327604830265045, -0.01178189367055893, 0.09540776163339615, 0.06561370193958282, -0.017085101455450058, -0.031296506524086, -0.06942930072546005, -0.06638207286596298, -0.17307314276695251, -0.10374918580055237, -0.16685496270656586, 0.07228758186101913, -0.14101159572601318, -1.0019933682769988e-07, 0.12259775400161743, -0.0017202645540237427, 0.13531231880187988, -0.0360899418592453, 0.13184881210327148, -0.08573167026042938, -0.09112462401390076, 0.12797094881534576, 0.015601941384375095, 0.12500959634780884, 0.10437652468681335, 0.10335085541009903, 0.02028902992606163, 0.12699614465236664, 0.09061212092638016, 0.17432396113872528, -0.06786227971315384, -0.03256036341190338, -0.09473839402198792, 0.019480137154459953, 0.010376226156949997, 0.030778922140598297, 0.002439534291625023, -0.015593688935041428, 0.1270076334476471, -0.13538536429405212, 0.017507173120975494, 0.05062180757522583, -0.014954235404729843, 0.009993534535169601, -0.09661093354225159, -0.12305223941802979, 0.056991592049598694, 0.15232083201408386, 0.059608690440654755, -0.09386365115642548, 0.13930517435073853, 0.030488058924674988, -0.08284628391265869, -0.03144596517086029, -0.09584104269742966, 0.11605127155780792, -0.09193940460681915, -0.04991010203957558, 0.08846740424633026, -0.16153231263160706, -0.11523370444774628, -0.01567578688263893, 0.0436612032353878, 0.014599482528865337, -0.006287091411650181, 0.05450304597616196, -0.011925946921110153, -0.0033192280679941177, 0.09555459767580032, 0.15646123886108398, -0.029733262956142426, -0.11752696335315704, -0.13816675543785095, 0.11082148551940918, 0.2047632932662964, -0.07645117491483688, 0.12793606519699097, 0.006658322177827358], "changes": {"1wk": -0.27010850363804434}}, {"text": "LIVE The latest news and updates on Trump's tariffs FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia Zacks Equity Research Thu, Jan 9, 2025, 4:14 PM 4 min read In This Article: AGIO -2.25% CSTL +1.70% Agios Pharmaceuticals AGIO announced that the FDA has accepted its supplemental new drug application (sNDA) seeking label expansion for its sole marketed drug, Pyrukynd, in thalassemia indication. A final decision is expected by Sep. 7, 2025. If approved, Pyrukynd will become the first oral therapy for use in all thalassemia subtypes. A commercial launch in this indication is expected before this year\u2019s end. The sNDA is supported by data from two phase III studies, ENERGIZE and ENERGIZE-T, which evaluated Pyrukynd for alpha or beta-thalassemia patients who are non-transfusion-dependent and transfusion-dependent, respectively. Both studies achieved their primary and key secondary endpoints. Similar regulatory filings have been submitted by Agios in the European Union, Kingdom of Saudi Arabia and United Arab Emirates, supported by data from the two studies. Pyrukynd is currently approved by the FDA to treat adults with pyruvate kinase deficiency, a rare and debilitating blood disorder. It is the sole marketed product in the company\u2019s portfolio. AGIO Stock\u2019s Performance In the past year, Agios\u2019 shares have surged nearly 50% against the industry\u2019s 15% decline. Zacks Investment Research Image Source: Zacks Investment Research Factors Responsible for the Uptick in AGIO Stock This surge in share price began at the onset of 2024 when Agios reported that the ENERGIZE study achieved its primary endpoint of hemoglobin response, as 42.3% of patients who received the drug achieved a hemoglobin response compared with 1.6% for placebo. Later in June, management reported similar results from the ENERGIZE-T study, which also achieved its primary endpoint of reduction in transfusion burden, as 30.4% of patients in the Pyrukynd arm achieved a transfusion reduction response compared with 12.6% in the placebo arm. In the third quarter of 2024, management significantly boosted its cash resources when AGIO added $1.1 billion from Royalty Pharma RPRX and France-based Servier following the FDA\u2019s approval of vorasidenib for a brain tumor called IDH-mutant diffuse glioma in August. Vorasidenib was a part of Agios\u2019 oncology business that was sold to Servier in 2021. Per the terms of the sale agreement between the two companies, Servier made a milestone payment of $200 million to Agios for this approval. In May, Agios inked a deal with Royalty Pharma to sell its royalty rights on potential net sales of vorasidenib in exchange for an upfront payment of $905 million contingent on the FDA\u2019s approval for the drug. Management intends to utilize the above funds to expand its pipeline and support potential product launches. Story Continues However, some of the stock gains were pared last month after Agios revealed that two thalassemia patients who received Pyrukynd across the ENERGIZE and ENERGIZE-T studies reported hepatocellular (liver) injury in the first six months of treatment. The regulatory filings by management identify this injury as a potential risk in thalassemia patients and propose monthly liver test monitoring during the first six months of treatment. AGIO\u2019s Zacks Rank Agios currently carries a Zacks Rank #3 (Hold). Agios Pharmaceuticals, Inc. Price Agios Pharmaceuticals, Inc. Price Agios Pharmaceuticals, Inc. price | Agios Pharmaceuticals, Inc. Quote Our Key Picks Among Biotech Stocks Some better-ranked stocks from the sector are Castle Biosciences CSTL and CytomX Therapeutics CTMX, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . Bottom-line estimates for Castle Biosciences have improved from a loss of 8 cents per share to earnings of 34 cents for 2024 in the past 60 days. During the same timeframe, loss per share estimates for 2025 have narrowed from $1.88 to $1.84. In the past year, shares of Castle Biosciences have surged 56%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%. In the past 60 days, estimates for CytomX Therapeutics\u2019 2024 loss per share have narrowed from 18 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 55 cents to 35 cents during the same timeframe. CTMX\u2019s shares have lost 38% in the past year. CytomX\u2019s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Royalty Pharma PLC (RPRX) : Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AGIO", "date": "2025-01-09T16:14:00", "sentiment": {"score": 0.9096202040091157, "confidence": 0.9202031493186951, "probabilities": {"positive": 0.9202031493186951, "negative": 0.010582945309579372, "neutral": 0.06921380758285522}}, "embedding": [-0.1420278251171112, -0.04362688213586807, -0.1066955178976059, -0.051570113748311996, 0.049902915954589844, -0.01867537386715412, -0.04258573800325394, 0.3082848787307739, 0.10995267331600189, 0.04840303584933281, -0.1003396138548851, 0.14226894080638885, -0.13707973062992096, 0.0029651024378836155, -0.03296022117137909, -0.03957164287567139, 0.09233050048351288, 0.04125162214040756, -0.16423961520195007, -0.03794341906905174, 0.011609596200287342, -0.027104750275611877, 0.11193607747554779, 0.0961560532450676, -0.00948336161673069, 0.002478152047842741, -0.09271925687789917, -0.014857473783195019, -0.13401474058628082, 0.01584695093333721, -0.05527304485440254, 0.0638711079955101, 0.07017391920089722, -0.08052349090576172, -0.04595370963215828, 0.03662630170583725, -0.1507544368505478, 0.07563185691833496, -0.07231777906417847, -0.06584349274635315, 0.1610422134399414, -0.15793196856975555, -0.17611780762672424, 0.025945182889699936, -0.044640183448791504, -0.13175132870674133, -0.022862911224365234, 0.028118139132857323, -0.0307057723402977, 0.12792211771011353, -0.15139281749725342, -0.045699380338191986, -0.020691312849521637, 0.014741063117980957, -0.1373724788427353, -0.08416479825973511, -0.0977572500705719, -0.09451930969953537, -0.09248068928718567, 0.04539675638079643, -0.023444779217243195, -0.05570247024297714, -0.07317254692316055, 0.016545532271265984, 0.09706711769104004, 0.04637591913342476, 0.09083050489425659, -0.03709800913929939, -0.017895471304655075, -0.10038378834724426, 0.14664238691329956, -0.030739478766918182, 0.0031389060895889997, 0.11391251534223557, -0.06588409841060638, 0.11627204716205597, 0.13437628746032715, 0.07205560803413391, 0.07256344705820084, -0.07011005282402039, 0.11865636706352234, 0.09663024544715881, 0.0799996629357338, 0.007044658996164799, 0.002063293009996414, 0.008427755907177925, -0.06621699035167694, 0.1969188153743744, -0.0040882062166929245, 0.0249999538064003, 0.1346832811832428, 0.06527811288833618, -0.04390884190797806, 0.0438607856631279, -0.015226464718580246, 0.0382748544216156, -0.05397288128733635, -0.02955087646842003, 0.008324835449457169, 0.014499226585030556, 0.01531926728785038, 0.016761619597673416, -0.09993630647659302, -0.058886200189590454, -0.10037769377231598, -0.051509253680706024, 0.021108761429786682, -0.12375406175851822, 0.03408847004175186, 0.028988264501094818, -0.10365870594978333, -0.011091742664575577, -0.007161526009440422, -0.04686833545565605, -0.1074521392583847, 0.14055337011814117, -0.04290255904197693, 0.00668194517493248, 0.13055378198623657, 0.07489503175020218, -0.00862511433660984, 0.060342904180288315, 0.020921431481838226, 0.000688907690346241, 0.1451978087425232, -0.046108875423669815, -0.13058024644851685, 1.443558049877236e-32, -0.013727137818932533, 0.05643707513809204, 0.04183163493871689, 0.027365582063794136, -0.050849638879299164, 0.025061793625354767, -0.02154545485973358, -0.05290916562080383, -0.09911571443080902, 0.052594732493162155, -0.14974111318588257, -0.03310558199882507, 0.004050978925079107, 0.015416247770190239, -0.13600191473960876, -0.0621352419257164, -0.057321272790431976, -0.027044858783483505, 0.037455964833498, 0.010952979326248169, 0.03510522097349167, 0.01939944550395012, -0.008764952421188354, 0.12127898633480072, -0.08995972573757172, 0.09637150168418884, -0.07628035545349121, 0.10777656733989716, -0.01563435047864914, 0.06926117837429047, 0.017886370420455933, -0.006915672216564417, 0.0006303333211690187, -0.22017896175384521, -0.12717266380786896, -0.08936665207147598, -0.15987268090248108, -0.046105124056339264, -0.04412141442298889, 0.09049040079116821, -0.09584654867649078, 0.09229879081249237, -0.12286689877510071, 0.02084418758749962, 0.03577035665512085, -0.10320618748664856, -0.11001518368721008, 0.03607501834630966, -0.019031934440135956, 0.02102622017264366, -0.01751914992928505, -0.06991660594940186, 0.05581199377775192, -0.04818468913435936, -0.03226302191615105, -0.05240302532911301, -0.13745659589767456, -0.0823698490858078, 0.057195499539375305, 0.07571031898260117, 0.13140824437141418, 0.056687019765377045, -0.036568496376276016, 0.012924164533615112, -0.08779564499855042, 0.10979081690311432, -0.009276567958295345, -0.059294503182172775, -0.21058954298496246, 0.09158138930797577, 0.05739077180624008, 0.020205125212669373, 0.08922141045331955, 0.06477830559015274, 0.0720532014966011, -0.11844991147518158, 0.05891551822423935, 0.13931994140148163, 0.0302591472864151, -0.021139703691005707, 0.02458721585571766, 0.008038289844989777, -0.0018197651952505112, 0.1196078211069107, -0.11327629536390305, 0.003044657176360488, -0.04143868386745453, 0.029665835201740265, -0.04866396263241768, -0.02711307629942894, 0.09994702786207199, -0.07127754390239716, -0.06186145544052124, 0.06798747926950455, 0.14043450355529785, -1.3172251740688692e-32, 0.029208863154053688, 0.026097681373357773, -0.022909894585609436, -0.09467901289463043, 0.01664113998413086, 0.09709451347589493, 0.13828089833259583, -0.013152588158845901, 0.12453478574752808, 0.014937188476324081, 0.1027275025844574, 0.11119421571493149, -0.03154975175857544, -0.053645744919776917, -0.04126683622598648, 0.04956149309873581, -0.012597005814313889, -0.03264056146144867, 0.01047379057854414, 0.03553357347846031, 0.021873343735933304, 0.20083072781562805, -0.05149959772825241, 0.07182884961366653, 0.05321848765015602, 0.024642163887619972, -0.046464953571558, 0.12616530060768127, 0.056201111525297165, -0.07089947909116745, -0.013788566924631596, 0.03387666493654251, -0.23788931965827942, 0.009977884590625763, -0.07804866135120392, -0.007177120074629784, 0.01456691324710846, -0.05407921224832535, -0.0815824419260025, -0.04486178979277611, 0.08302135765552521, 0.04090981185436249, 0.05894779413938522, 0.12197665870189667, 0.0871138721704483, 0.021807849407196045, -0.029737254604697227, -0.06890127062797546, 0.13095723092556, -0.056834425777196884, -0.04472491890192032, 0.10005968809127808, 0.0124685512855649, 0.06904946267604828, 0.08276496827602386, -0.03374245762825012, 0.0483621209859848, -0.06691861152648926, -0.19093844294548035, 0.009083811193704605, 0.0194479338824749, -0.0352444052696228, 0.0009889723733067513, -0.016250239685177803, 0.07812000811100006, 0.08330978453159332, 0.032872166484594345, 0.020905889570713043, 0.13783398270606995, 0.010495858266949654, 0.03534645587205887, -0.028851795941591263, -0.07126148790121078, -0.1771840751171112, -0.035368662327528, 0.19204476475715637, -0.013442343100905418, -0.026792004704475403, -0.11469323933124542, -0.029874855652451515, -0.028528261929750443, -0.10423389822244644, -0.07173529267311096, 0.030103081837296486, -0.010181194171309471, 0.03021891787648201, 0.09145215898752213, -0.020627086982131004, -0.05972137302160263, -0.02408788725733757, -0.1271965503692627, -0.10173588991165161, -0.010040732100605965, 0.15582188963890076, 0.039301797747612, -1.0088211865877383e-07, 0.06867631524801254, -0.08105336129665375, -0.030310992151498795, -0.0015756554203107953, 0.013921215198934078, -0.015443351119756699, -0.033285338431596756, 0.08350718766450882, 0.012689607217907906, 0.13522186875343323, -0.051478996872901917, 0.1497085690498352, -0.028172947466373444, 0.002055395394563675, -0.00613868422806263, 0.008146891370415688, 0.0072152139618992805, 0.0880482867360115, -0.00615917332470417, -0.05861162021756172, -0.056998759508132935, 0.027225449681282043, -0.03309367597103119, -0.09689316898584366, 0.027138706296682358, -0.004096594639122486, 0.07104657590389252, -0.019871193915605545, 0.04128362983465195, -0.06507932394742966, 0.024584902450442314, -0.026093371212482452, 0.09659861028194427, 0.049351975321769714, 0.02372157759964466, -0.07412979006767273, 0.016433317214250565, 0.10728341341018677, 0.07785515487194061, -0.017016401514410973, -0.02330559305846691, -0.008210306987166405, -0.028227947652339935, 0.04810871183872223, 0.004518577829003334, 0.005375346634536982, -0.10756008327007294, -0.05639657378196716, 0.03288727253675461, -0.08468195050954819, 0.05643349885940552, 0.038097865879535675, -0.09356650710105896, 0.010577515698969364, -0.0112734604626894, 0.14795124530792236, -0.02404225803911686, -0.05496745556592941, -0.05849631503224373, -0.09569627046585083, 0.1233002096414566, -0.2270469069480896, 0.02160574495792389, 0.02029183693230152], "changes": {"1wk": -3.31202629370555}}]